+

WO2025174659A1 - Net-zero current scheme for nanopore system - Google Patents

Net-zero current scheme for nanopore system

Info

Publication number
WO2025174659A1
WO2025174659A1 PCT/US2025/014933 US2025014933W WO2025174659A1 WO 2025174659 A1 WO2025174659 A1 WO 2025174659A1 US 2025014933 W US2025014933 W US 2025014933W WO 2025174659 A1 WO2025174659 A1 WO 2025174659A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanopore
membrane
unit cell
array
zero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/014933
Other languages
French (fr)
Inventor
Rico OTTO
Christian Urban
John Walker
Boyan Boyanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Illumina Inc
Original Assignee
Illumina Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Illumina Inc filed Critical Illumina Inc
Publication of WO2025174659A1 publication Critical patent/WO2025174659A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/48707Physical analysis of biological material of liquid biological material by electrical means
    • G01N33/48721Investigating individual macromolecules, e.g. by translocation through nanopores

Definitions

  • the present technology generally relates to devices for determining the sequence of a biopolymer, such as a polynucleotide or polypeptide, and more specifically to nanopore sequencing devices.
  • Various polynucleotide sequencing techniques involve performing a large number of controlled reactions on support surfaces or within predefined reaction chambers. The controlled reactions may then be observed or detected, and subsequent analysis may help identify the properties of the polynucleotide involved in the reaction. Examples of such sequencing techniques include next-generation sequencing or massive parallel sequencing involving sequencing-by-ligation, sequencing-by-synthesis, reversible terminator chemistry, or pyrosequencing approaches.
  • Embodiment 1 A method of generating net- zero or near-zero current scheme in an array of nanopore unit cells, the method comprising:
  • Embodiment 2 The method as defined in Embodiment 1 , wherein the states comprise: a unit cell with an open well where no membrane was formed, a unit cell with a burst or non-intact membrane, a unit cell with an intact membrane where no nanopore was formed, a unit cell with a membrane having an open nanopore without an analyte, a unit cell with a membrane having a nanopore in which an analyte is inserted, or a unit cell with a membrane having multiple nanopores.
  • Embodiment 3 The method as defined in Embodiment 1, wherein a unit cell with an open well where no membrane was formed, a unit cell with a burst or nonintact membrane, a unit cell with an intact membrane where no nanopore was formed, a unit cell with a membrane having an open nanopore without an analyte, and/or a unit cell with a membrane having multiple nanopores is used to balance currents in the array of nanopore unit cells to achieve net-zero or near-zero current.
  • Embodiment 4 The method as defined in Embodiment 1 , comprising:
  • Embodiment 5 The method as defined in Embodiment 4, wherein the sub-groups comprise sequencing, ejecting, recharging, and capturing.
  • Embodiment 6 The method as defined in Embodiment 5, wherein the sequencing and capturing sub-groups are associated with forward currents, and wherein the ejecting and recharging sub-groups are associated with reverse currents.
  • Embodiment 7 The method as defined in Embodiment 1 , comprising determining the state of an individual nanopore unit cell based on the magnitude and/or direction of the current flowing through the individual nanopore unit cell.
  • Embodiment s The method as defined in Embodiment 1, further comprising, in response to determining that total current of the array is not zero or is above a predetermined threshold, changing the state of at least one nanopore unit cell to change the magnitude and/or direction a corresponding current.
  • Embodiment 9 The method as defined in Embodiment 1 , further comprising determining waveforms to be applied to nanopore unit cells in the array to achieve net-zero or near- zero total current of the array by a FPGA.
  • Embodiment 10 The method as defined in Embodiment 1, wherein the waveform applied to at least one nanopore unit cell is AC.
  • Embodiment 11 The method as defined in Embodiment 10, wherein the AC waveforms applied to at least two of the nanopore unit cells have different phases.
  • Embodiment 12 The method as defined in Embodiment 4, wherein a first and second sub-groups are determined, wherein nanopore unit cells included in the first subgroup have forward currents, and wherein nanopore unit cells included in the second sub-group have reverse currents.
  • Embodiment 13 The method as defined in Embodiment 1, further comprising monitoring the total current of the array of nanopore unit cells.
  • Embodiment 14 The method as defined in Embodiment 4, further comprising, in response to determining that the total current is not zero or is above a predetermined threshold, re-dividing the array of nanopore unit cells.
  • Embodiment 15 The method as defined in Embodiment 4, wherein assigning nanopore unit cells to each sub-groups is based at least on a conductivity associated with the individual nanopore unit cells.
  • Embodiment 16 A nanopore device, comprising:
  • an application specific integrated circuit (ASIC) layer disposed below the array of nanopore unit cells, wherein the ASIC layer comprises an array of active circuitries;
  • a processor configured to:
  • Embodiment 17 The nanopore device as defined in Embodiment 16, further comprising:
  • Embodiment 18 The nanopore device as defined in Embodiment 16, wherein an electrolyte solution is filled in the cis well.
  • Embodiment 19 The nanopore device as defined in Embodiment 16, further comprising:
  • trans electrode wherein the trans electrode is disposed in an individual trans well, and wherein the trans electrode is electrically connected with a corresponding active circuitry in the ASIC.
  • Embodiment 20 The nanopore device as defined in Embodiment 16, wherein the state comprises an open well where no membrane was formed, an intact membrane where no nanopore was formed, a membrane with an open nanopore without an analyte, a membrane with a nanopore in which an analyte is inserted, or a membrane with multiple nanopores.
  • Embodiment 21 The nanopore device as defined in Embodiment 16, wherein the processor is configured to determine the state of a nanopore unit cell based on the magnitude and/or direction of the current flowing through the cell.
  • Embodiment 22 The nanopore device as defined in Embodiment 16, wherein the processor is configured to change the states of at least one nanopore unit cell in response to determining that the net current of the array is not zero or is above a predetermined threshold magnitude.
  • Embodiment 23 The nanopore device as defined in Embodiment 16, wherein the processor is further configured to determine waveforms which can achieve net- zero or near-zero total current in the array of nanopore unit cells.
  • Embodiment 24 The nanopore device as defined in Embodiment 23, wherein the waveforms applied to at least two of the nanopore unit cells have a different phases.
  • Embodiment 25 The nanopore device as defined in Embodiment 16, wherein the processor is a FPGA.
  • Embodiment 26 The nanopore device as defined in Embodiment 19, wherein the voltage applied to each individual trans electrode is independently controlled.
  • any features of the device and/or of the array disclosed herein may be combined together in any desirable manner and/or configuration. Further, it is to be understood that any features of the method of using the device may be combined together in any desirable manner. Moreover, it is to be understood that any combination of features of this method and/or of the device may be used together and/or may be combined with any of the examples disclosed herein. Still, further, it is to be understood that any feature or combination of features of any of the devices and/or of the arrays and/or of any of the methods may be combined together in any desirable manner and/or may be combined with any of the examples disclosed herein.
  • FIG. 1A illustrates one embodiment of a nanopore sequencing system.
  • FIG. 2 illustrates a cross-sectional view of one embodiment a nanopore sensor device.
  • FIG. 3A illustrates an equivalent circuit diagram of the nanopore sensor device of FIG. 2.
  • FIG. 3B shows effects on Vois in response to changes in Rptot.
  • FIG. 4 illustrates the current flows in nanopore unit cells in a net-zero current scheme.
  • FIG. 5A depicts the different modes of operation in a nanopore unit cell during an example course of sequencing.
  • FIG. 5B shows an example waveform that may be used in connection with some modes depicted in FIG. 5A.
  • FIG. 6A illustrates one example scheme of balancing currents to achieve net-zero or near zero total current in the nanopore array.
  • FIG. 6B illustrates one example scheme of balancing currents to achieve net-zero or near zero total current in the nanopore array.
  • FIG. 7A, FIG. 7B and FIG. 7C illustrate some example schemes of balancing currents to achieve net- zero or near zero total current in the nanopore array.
  • FIG. 9 shows an example of current ratios between various states that can achieve a net- zero current scheme.
  • the term “operably connected” refers to a configuration of elements, wherein an action or reaction of one element affects another element, but in a manner that preserves each element's functionality.
  • the term “membrane” refers to a non-permeable or semi- permeable barrier or other sheet that separates two liquid/gel chambers (e.g., a cis well and a trans well) which can contain the same compositions or different compositions therein. Any membrane may be used in accordance with the present disclosure, as long as the membrane can include a transmembrane nanoscale opening and can maintain a potential difference across the membrane.
  • the membrane may be a monolayer or a multilayer membrane. A multilayer membrane includes two or more layers.
  • the membrane may be formed of materials of non- biological or biological origin.
  • An example membrane that is made from non-biological materials are block copolymer.
  • the term is a “block copolymer” is intended to refer to a polymer having at least a first portion or block that includes a first type of monomer, and at least a second portion or bloc” that is coupled directly or indirectly to the first portion and includes a second, different type of monomer.
  • Block copolymers include, but are not limited to, diblock copolymers and triblock copolymers.
  • a “diblock copolymer” is intended to refer to a block copolymer that includes a first and second blocks coupled directly or indirectly to one another.
  • the first block may be hydrophilic and the second block may be hydrophobic, in which case the diblock copolymer may be referred to as an “AB” copolymer where “A” refers to the hydrophilic block and “B” refers to the hydrophobic block.
  • a “triblock copolymer” is intended to refer to a block copolymer that includes a first, second, and third blocks coupled directly or indirectly to one another.
  • the first and third blocks may include, or may consist essentially of, the same type of monomer (repeating unit) as one another, and the second block may include a different type of monomer (repeating unit).
  • the first block may be hydrophilic
  • the second block may be hydrophobic
  • the third block may be hydrophilic and includes the same type of monomer as the first block, in which case the triblock copolymer may be referred to as an “ABA” copolymer where “A” refers to the hydrophilic blocks and “B” refers to the hydrophobic block.
  • the block copolymers may be formed into a bilayer membrane in which the hydrophilic blocks are positioned on the outward of the bilayer membrane and in which the hydrophobic blocks are positioned inward of the bilayer membrane.
  • Example hydrophilic A blocks include, but are not limited to, a polymer selected from the group consisting of: N-vinyl pyrrolidone, polyacrylamide, zwitterionic polymer (Zwitt), hydrophilic polypeptide, poly(ethylene glycol) (PEG), carbon-oxygen- nitrogen containing polymers (C x O y N Z ), polyacrylic acid, and combinations thereof.
  • a polymer selected from the group consisting of: N-vinyl pyrrolidone, polyacrylamide, zwitterionic polymer (Zwitt), hydrophilic polypeptide, poly(ethylene glycol) (PEG), carbon-oxygen- nitrogen containing polymers (C x O y N Z ), polyacrylic acid, and combinations thereof.
  • An example membrane that is made from non-biological materials are solid- state materials.
  • the solid-state membrane can be a monolayer, such as a coating or film on a supporting substrate (i.e., a solid support), or a freestanding element.
  • the solid-state membrane can also be a composite of multilayered materials in a sandwich configuration. Any material not of biological origin may be used, as long as the resulting membrane can include a transmembrane nanoscale opening and can maintain a potential difference across the membrane.
  • the membranes may include organic materials, inorganic materials, or both.
  • suitable solid-state materials include, for example, microelectronic materials, insulating materials (e.g., silicon nitride (SisNA), aluminum oxide (AI2O3), hafnium oxide (HfCh), tantalum pentoxide (Ta2Os), silicon oxide (SiCh), etc.), some organic and inorganic polymers (e.g., polyamide, plastics, such as polytetrafluoroethylene (PTFE), or elastomers, such as two-component addition-cure silicone rubber), and glasses.
  • insulating materials e.g., silicon nitride (SisNA), aluminum oxide (AI2O3), hafnium oxide (HfCh), tantalum pentoxide (Ta2Os), silicon oxide (SiCh), etc.
  • organic and inorganic polymers e.g., polyamide, plastics, such as polytetrafluoroethylene (PTFE), or elastomers, such as two-component addition-cure silicone
  • the solid-state membrane can be made from a monolayer of graphene, which is an atomically thin sheet of carbon atoms densely packed into a two-dimensional honeycomb lattice, a multilayer of graphene, or one or more layers of graphene mixed with one or more layers of other solid-state materials.
  • a graphene-containing solid-state membrane can include at least one graphene layer that is a graphene nanoribbon or graphene nanogap, which can be used as an electrical sensor to characterize the target polynucleotide. It is to be understood that the solid-state membrane can be made by any suitable method, for example, chemical vapor deposition (CVD).
  • a graphene membrane can be prepared through either CVD or exfoliation from graphite.
  • synthetic refers to a membrane material that is not of biological origin (e.g., polymeric materials, synthetic phospholipids, solid-state membranes, or combinations thereof).
  • a synthetic phospholipid bilayer can be formed, for example, from two opposing layers of phospholipids, which are arranged such that their hydrophobic tail groups face towards each other to form a hydrophobic interior, whereas the hydrophilic head groups of the lipids face outwards towards the aqueous environment on each side of the bilayer.
  • Lipid bilayers also can be formed, for example, by a method in which a lipid monolayer is carried on an aqueous solution/air interface past either side of an aperture that is substantially perpendicular to that interface.
  • the lipid is normally added to the surface of an aqueous electrolyte solution by first dissolving it in an organic solvent and then allowing a drop of the solvent to evaporate on the surface of the aqueous solution on either side of the aperture. Once the organic solvent has at least partially evaporated, the solution/air interfaces on either side of the aperture are physically moved up and down past the aperture until a bilayer is formed.
  • Other suitable methods of bilayer formation include tip-dipping, painting bilayers, and patchclamping of liposome bilayers. Any other methods for obtaining or generating lipid bilayers may also be used.
  • the diameter of the nanoscale opening extending through the nanopore structure can vary along its length (i.e., from one side of the membrane to the other side of the membrane), but at any point is on the nanoscale (i.e., from about 1 nm to about 100 nm, or to less than 1000 nm).
  • the nanopore include, for example, biological nanopores, solid-state nanopores, and biological and solid-state hybrid nanopores.
  • a nanopore refers to a pore having an opening with a diameter at its most narrow point of about 0.3 nm to about 2 nm.
  • solid-state nanopore is intended to mean a nanopore whose structure portion is defined by a solid-state membrane.
  • a solid-state nanopore can be formed of an inorganic or organic material.
  • Solid-state nanopores include, for example, silicon nitride nanopores, silicon dioxide nanopores, solid-state nanopores in polymeric membranes (e.g., polyimide), and graphene nanopores.
  • the application of the potential difference across a nanopore may force the translocation of a nucleic acid or a polynucleotide through or relative to the nanopore.
  • One or more signals are generated that correspond to the translocation of the nucleotide through or relative to the nanopore. Accordingly, as a target polynucleotide, or as a mononucleotide or a probe derived from the target polynucleotide or mononucleotide, transits through or relative to the nanopore, the current across the membrane changes due to base-dependent (or probe dependent) blockage of the nanopore constriction, for example.
  • the signal from that change in current can be measured using any of a variety of methods.
  • Each signal is unique to the species of nucleotide(s) (or probe) in the nanopore, such that the resultant signal can be used to determine a characteristic of the polynucleotide. For example, the identity of one or more species of nucleotide(s) (or probe) that produces a characteristic signal can be determined.
  • the polynucleotide may or may not completely translocate through the nanopore and out into the trans well.
  • nanopore sequencer or “nanopore sensor device” refers to any of the devices disclosed herein that can be used for nanopore sequencing.
  • the nanopore is immersed in an electrolyte and a potential difference is applied across the membrane.
  • the potential difference is an electric potential difference or an electrochemical potential difference.
  • An electrical potential difference can be imposed across the membrane via a voltage source that injects or administers current to at least one of the ions of the electrolyte contained in the cis well or one or more of the trans wells.
  • An electrochemical potential difference can be established by a difference in ionic composition of the cis and trans wells in combination with an electrical potential.
  • the different ionic composition can be, for example, different ions in each well or different concentrations of the same ions in each well.
  • Apparatuses and methods include sequencing polynucleotides and sequencing polypeptides and include providing genomics analysis and proteomics analysis.
  • a “peptide” refers to two or more amino acids joined together by an amide bond (that is, a “peptide bond”).
  • Peptides comprise up to or include 50 amino acids.
  • Peptides may be linear or cyclic.
  • Peptides may be a, 0, y, 5, or higher, or mixed.
  • Peptides may comprise any mixture of amino acids as defined herein, such as comprising any combination of D, L, a, 0, y, 5, or higher amino acids.
  • a “protein” refers to an amino acid sequence having 51 or more amino acids.
  • nucleotide includes a nitrogen containing heterocyclic base, a sugar, and one or more phosphate groups. Nucleotides are monomeric units of a nucleic acid sequence. Examples of nucleotides include, for example, ribonucleotides or deoxyribonucleotides. In ribonucleotides (RNA), the sugar is a ribose, and in deoxyribonucleotides (DNA), the sugar is a deoxyribose, i.e., a sugar lacking a hydroxyl group that is present at the 2' position in ribose.
  • RNA ribonucleotides
  • DNA deoxyribonucleotides
  • the nitrogen, containing a heterocyclic base can be a purine base or a pyrimidine base.
  • Purine bases include adenine (A) and guanine (G), and modified derivatives or analogs thereof.
  • Pyrimidine bases include cytosine (C), thymine (T), and uracil (U), and modified derivatives or analogs thereof.
  • the C-l atom of deoxyribose is bonded to N-l of a pyrimidine or N-9 of a purine.
  • the phosphate groups may be in the mono- , di-, or tri-phosphate form.
  • nucleobase is a heterocyclic base such as adenine, guanine, cytosine, thymine, uracil, inosine, xanthine, hypoxanthine, or a heterocyclic derivative, analog, or tautomer thereof.
  • a nucleobase can be naturally occurring or non-natural.
  • nucleobases are adenine, guanine, thymine, cytosine, uracil, xanthine, hypoxanthine, 8-azapurine, purines substituted at the 8 position with methyl or bromine, 9-oxo-N6-methyladenine, 2-aminoadenine, 7-deazaxanthine, 7-deazaguanine, 7- deaza-adenine, N4-ethanocytosine, 2,6- diaminopurine, N6-ethano-2,6-diaminopurine, 5- methylcytosine, 5-(C3-C6)- alkynylcytosine, 5-fluorouracil, 5-bromouracil, thiouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridine, isocytosine, isoguanine, inosine, 7,8-dimethylalloxazine, 6-dihydrothymine, 5-
  • polynucleotide refers to a molecule that includes a sequence of nucleotides that are bonded to one another.
  • a polynucleotide is one nonlimiting example of a polymer.
  • examples of polynucleotides include deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and analogues thereof such as locked nucleic acids (LNA) and peptide nucleic acids (PNA).
  • a polynucleotide may be a single stranded sequence of nucleotides, such as RNA or single stranded DNA, a double stranded sequence of nucleotides, such as double stranded DNA, or may include a mixture of a single stranded and double stranded sequences of nucleotides.
  • Double stranded DNA includes genomic DNA, and PCR and amplification products. Single stranded DNA (ssDNA) can be converted to dsDNA and vice- versa.
  • Polynucleotides may include non-naturally occurring DNA, such as enantiomeric DNA, LNA, or PNA.
  • nucleotides in a polynucleotide may be known or unknown.
  • polynucleotides for example, a probe, primer, expressed sequence tag (EST) or serial analysis of gene expression (SAGE) tag
  • genomic DNA genomic DNA fragment, exon, intron, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozyme, cDNA
  • mRNA messenger RNA
  • transfer RNA ribosomal RNA
  • ribozyme cDNA
  • recombinant polynucleotide non-natural polynucleotide, branched polynucleotide, plasmid, vector, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probe, primer or amplified copy of any of the foregoing.
  • nucleic acid may be used interchangeably with “polynucleotide” to refer to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form and, unless otherwise limited, encompasses known analogs of natural nucleotides that hybridize to nucleic acids in manner similar to naturally occurring nucleotides, such as peptide nucleic acids (PNAs) and phosphorothioate DNA. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.
  • Nucleotides include but are not limited to, ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, TTP, dUTP, 5-methyl-CTP, 5- methyl-dCTP, ITP, diTP, 2-amino-adenosine-TP, 2-amino-deoxyadenosine-TP, 2- thiothymidine triphosphate, pyrrolo-pyrimidine triphosphate, and 2-thiocytidine, as well as the alphathiotriphosphates for all of the above, and 2'-O-methyl-ribonucleotide triphosphates for all the above bases.
  • Modified bases include, but are not limited to, 5-Br-UTP, 5-Br-dUTP, 5- F-UTP, 5-F-dUTP, 5-propynyl dCTP, and 5-propynyl-dUTP.
  • a template polynucleotide chain may be any sample that is to be sequenced, and may be composed of DNA, RNA, or analogs thereof (e.g., peptide nucleic acids).
  • the source of the template (or target) polynucleotide chain can be genomic DNA, messenger RNA, or other nucleic acids from native sources.
  • the template polynucleotide chain that is derived from such sources can be amplified prior to use. Any of a variety of known amplification techniques can be used including, but not limited to, polymerase chain reaction (PCR), rolling circle amplification (RCA), multiple displacement amplification (MDA), or random primer amplification (RPA).
  • PCR polymerase chain reaction
  • RCA rolling circle amplification
  • MDA multiple displacement amplification
  • RPA random primer amplification
  • Template/target polynucleotide chains can optionally be derived from non-natural libraries.
  • Non-natural nucleic acids can have native DNA or RNA compositions or can be analogs thereof.
  • a population of template/target polynucleotide chains, or amplicons thereof can have an average strand length that is desired or appropriate for a particular sequencing device.
  • the average strand length can be less than about 100,000 nucleotides, about 50,000 nucleotides, about 10,000 nucleotides, about 5,000 nucleotides, about 1,000 nucleotides, about 500 nucleotides, about 100 nucleotides, or about 50 nucleotides.
  • the average strand length can be greater than about 10 nucleotides, about 50 nucleotides, about 100 nucleotides, about 500 nucleotides, about 1,000 nucleotides, about 5,000 nucleotides, about 10,000 nucleotides, about 50,000 nucleotides, or about 100,000 nucleotides.
  • the average strand length can be greater than about 10 kilo nucleotides, about 50 kilo nucleotides, about 100 kilo nucleotides, about 500 kilo nucleotides, about 1,000 kilo nucleotides, about 5,000 kilo nucleotides, about 10,000 kilo nucleotides, about 50,000 kilo nucleotides, or about 100,000 kilo nucleotides.
  • the average strand length can be greater than about 10 mega nucleotides, about 50 mega nucleotides, about 100 mega nucleotides, about 500 mega nucleotides, about 1,000 mega nucleotides, about 5,000 mega nucleotides, about 10,000 mega nucleotides, about 50,000 mega nucleotides, or about 100,000 mega nucleotides.
  • the average strand length for a population of target polynucleotide chains, or amplicons thereof, can be in a range between a maximum and minimum value set forth above.
  • a population of template/target polynucleotide chains can be produced under conditions or otherwise configured to have a maximum length for its members.
  • the maximum length for the members can be less than about 100,000 nucleotides, about 50,000 nucleotides, about 10,000 nucleotides, about 5,000 nucleotides, about 1,000 nucleotides, about 500 nucleotides, about 100 nucleotides or about 50 nucleotides.
  • the maximum length for the members can be less than about 100,000 kilo nucleotides, about 50,000 kilo nucleotides, about 10,000 kilo nucleotides, about 5,000 kilo nucleotides, about 1,000 kilo nucleotides, about 500 kilo nucleotides, about 100 kilo nucleotides or about 50 kilo nucleotides.
  • the maximum length for the members can be less than about 100,000 mega nucleotides, about 50,000 mega nucleotides, about 10,000 mega nucleotides, about 5,000 mega nucleotides, about 1,000 mega nucleotides, about 500 mega nucleotides, about 100 mega nucleotides or about 50 mega nucleotides.
  • a population of template polynucleotide chains, or amplicons thereof can be produced under conditions or otherwise configured to have a minimum length for its members.
  • the minimum length for the members can be more than about 10 kilo nucleotides, about 50 kilo nucleotides, about 100 kilo nucleotides, about 500 kilo nucleotides, about 1,000 kilo nucleotides, about 5,000 kilo nucleotides, about 10,000 kilo nucleotides, about 50,000 kilo nucleotides, or about 100,000 kilo nucleotides.
  • the minimum length for the members can be more than about 10 mega nucleotides, about 50 mega nucleotides, about 100 mega nucleotides, about 500 mega nucleotides, about 1,000 mega nucleotides, about 5,000 mega nucleotides, about 10,000 mega nucleotides, about 50,000 mega nucleotides, or about 100,000 mega nucleotides.
  • the maximum and minimum strand length for template polynucleotide chains in a population can be in a range between a maximum and minimum value set forth above.
  • the term “signal” is intended to mean an indicator that represents information. Signals include, for example, an electrical signal and an optical signal.
  • the term “electrical signal” refers to an indicator of an electrical quality that represents information.
  • the indicator can be, for example, current, voltage, tunneling, resistance, potential, conductance, inductance, impedance, or a transverse electrical effect (and any time- derivatives or transients of theses).
  • An “electronic current” or “electric current” refers to a flow of electric charge.
  • an electrical signal may represent an ionic current passing through a nanopore, and the ionic current may flow when an electric potential difference is applied across the nanopore.
  • substrate refers to a rigid, solid support that is insoluble in aqueous liquid and is incapable of passing a liquid absent an aperture, port, or other liquid conduit.
  • the substrate may have wells or chambers defined therein.
  • suitable substrates include wafers, glass and modified or functionalized glass, polymers (including acrylics, polystyrene, and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, polytetrafluoroethylene (PTFE) (such as TEFLON® from Chemours), cyclic olefins/cyclo-olefin polymers (COP) (such as ZEONOR® from Zeon), poly imides, polymethyleneoxide, etc.), nylon, ceramics, silica or silica-based materials, silicon and modified silicon, carbon, metals, inorganic glasses, and optical fiber bundles.
  • polymers including acrylics, polystyrene, and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, polytetrafluoroethylene (PTFE) (such as TEFLON® from Chemours), cyclic
  • top, bottom, lower, upper, on, etc. are used herein to describe the device/nanopore sequencer and/or the various components of the device. It is to be understood that these directional terms are not meant to imply a specific orientation but are used to designate relative orientation between components. The use of directional terms should not be interpreted to limit the examples disclosed herein to any specific orientation(s). As used herein, the terms “upper,” “lower,” “vertical,” “horizontal” and the like are meant to indicate relative orientation.
  • translocation it is meant that an analyte (e.g., a polynucleotide, such as DNA) moves relative the nanopore opening, but the analyte does not need to move through the nanopore and exit other side of the nanopore opening.
  • the analyte may enter any side of the nanopore, such as the cis side and/or trans side) and may optionally exit the other side of the nanopore opening.
  • the analyte may be translocated multiples times relative to the nanopore in one or more directions, such as cis-to- trans direction, trans-to-cis direction, or both. It is contemplated that any embodiment herein comprising translocation may refer to non-electrophoretic translocation or electrophoretic translocation, unless specifically noted.
  • the terms "well,” “cavity,” and “chamber” are used synonymously and refer to a discrete feature defined in the device that can contain a fluid (e.g., liquid, gel, gas).
  • a "cis well” is a chamber that contains or is partially defined by a cis electrode, and is also fluidically connected to a trans well through a respective nanopore. Examples of an array of the present device may comprise one or more cis wells where an individual cis well is a common chamber for a group of trans wells.
  • Each "trans well” is a single chamber that contains or is partially defined by its own trans electrode and is also fluidically connected to a cis well. Each trans well is electrically isolated from the other trans well.
  • each trans well is connected to a respective stimulus source and to a respective amplifier (e.g., an on-chip amplifier integrated with a trans electrode) to amplify electrical signals passing through respective nanopores associated with each of the trans wells.
  • the trans wells are connected to a single stimulus source which individually addresses the trans wells via multiplexing.
  • the cross-section of a well taken parallel to a surface of a substrate, at least partially defining the well can be curved, square, polygonal, hyperbolic, conical, angular, etc.
  • One type of nanopore sequencing is strand sequencing.
  • One type of strand sequencing involves the use of a polynucleotide binding protein, such as a motor protein or a helicase to control the movement of the polynucleotide through the nanopore.
  • a polynucleotide binding protein may be used to simultaneously separate the double stranded polynucleotide and control the rate of translocation of the resultant single strand through the nanopore.
  • Another type of strand sequencing involves modifying nucleotides on a strand of polynucleotide to carry a reporter, where the reports include tags or labels to produce a detectable signal.
  • the modified polynucleotide can be translocated through the nanopore (i.e., protein nanopore, solid state nanopore, hybrid nanopore) without a polynucleotide binding protein to control the movement of the polynucleotide.
  • the modified polynucleotide nucleotides on a strand of polynucleotide are described in United States Patent Application Publication US 2009/0035777 Al assigned to Roche Sequencing Solutions Inc. (Pleasanton, California, United States of America).
  • Another type of strand sequencing involves modifying nucleotides on a strand of polynucleotide to carry a modification, where the modifications can arrest or slow translocation when encountering the nanopore.
  • the modified polynucleotide can be translocated through the nanopore (i.e., protein nanopore, solid state nanopore, hybrid nanopore) without a polynucleotide binding protein to control the movement of the polynucleotide.
  • application of a voltage can move one nucleotide and its attached modification through the nanopore at a time.
  • modified polynucleotide nucleotides on a strand of polynucleotide are described in PCT International Published Patent Application WO2024/228928 Al by applicant Illumina, Inc. (San Diego, California, United States of America).
  • One type of nanopore sequencing involves disposing a polynucleotide within a nanopore.
  • the polynucleotide includes a formed duplex.
  • the duplex may be extended with a polymerase within the nanopore instrument.
  • a potential is applied across a nanopore, the duplex or extended duplex is held within the nanopore since the size of the constriction of the nanopore inhibits passage of the duplex completely through the nanopore.
  • the electrical signal of the duplex held within the nanopore is used to identify the polynucleotide sequencing. Detecting a polynucleotide duplex is described in PCT International Published Patent Application WO2023/049682A1 Al by applicant Illumina, Inc. (San Diego, California, United States of America).
  • Nanopore sequencing as described herein may involve using binding proteins (e.g., motor proteins, helicases) and/or using polymerases. Other types of nanopore sequencing may use exonucleases.
  • Analytes have been described herein as polynucleotides. Analytes may further include peptides, polypeptides, proteins, and constructs thereof.
  • controller 1011 can be implemented or performed by a machine, such as a processor configured with specific instructions, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein.
  • DSP digital signal processor
  • ASIC application specific integrated circuit
  • FPGA field programmable gate array
  • a processor can be a microprocessor, but in the alternative, the processor can be a controller, microcontroller, or state machine, combinations of the same, or the like.
  • a processor or group of processors for performing the methods described herein may be of various types, including programmable devices (e.g., CPLDs and FPGAs) and non-programmable devices such as gate array ASICs or general-purpose microprocessors.
  • a processor can also be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration.
  • systems described herein may be implemented using a discrete memory chip, a portion of memory in a microprocessor, flash, EPROM, or other types of memory.
  • a hardware platform for providing a computational environment may be used.
  • the hardware platform may comprise a processor (e.g., CPU) and a memory such as random-access memory (RAM).
  • graphics processing units GPUs can be used.
  • hardware platforms for performing computational methods as described herein comprise one or more computer systems with one or more processors.
  • smaller computers are clustered together to yield a supercomputer network.
  • the hardware platform may be specially constructed for the required purposes, or it may be a general-purpose computer (or a group of computers) selectively activated or reconfigured by a computer program and/or data structure stored in the computer.
  • a group of processors performs some or all of the described functionalities collaboratively (e.g., via a network or cloud computing) and/or in parallel.
  • a software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM, or any other form of computer-readable storage medium.
  • An exemplary storage medium can be coupled to the processor such that the processor can read information from, and write information to, the storage medium. In the alternative, the storage medium can be integral to the processor.
  • the processor and the storage medium can reside in an ASIC.
  • a software module can comprise computer-executable instructions which cause a hardware processor to execute the computer-executable instructions.
  • FIG. IB illustrates an example of a portion of one of the nanopore unit cells.
  • the nanopore unit cell may include a membrane 118.
  • the membrane 118 can be formed from any suitable natural and/or synthetic material.
  • the membrane 118 may also be formed of a non-permeable or semi-permeable material.
  • the membrane 118 includes a block copolymer structure or a bilipid layer.
  • the nanopore unit cell may further include a nanopore 120, which may be any of the biological nanopores, solid-state nanopores, and hybrid nanopores.
  • the nanopore 120 may be a hollow defined by, for example: a polynucleotide structure, a polypeptide structure, or a solid-state structure, e.g., a carbon nanotube, which is disposed in the membrane 118.
  • the membrane 118 may be a synthetic membrane (e.g., a solid-state membrane, one example of which is silicon nitride), and the nanopore 120 is in a hollow extending through the membrane 118.
  • a biological nanopore may be formed of peptides or polynucleotides and deposited in a block copolymer membrane, e.g., a synthetic polymeric membrane.
  • a solid-state nanopore may be formed as a nanoscale opening in a membrane (e.g., silicon-based, graphene, or polymer membrane).
  • the membrane 118 separates the nanopore unit cell into a cis compartment/well and a trans compartment/well.
  • a target polynucleotide can translocate from the cis well, relative to the nanopore 120, to the trans well.
  • a cis electrode 114 is associated with the cis compartment, and a trans electrode 122 is associated with the trans compartment.
  • the electrodes may be used to apply a voltage across the nanopore, thus driving ionic current flows through the nanopore 120 and exerting an electric force on the target polynucleotide.
  • the electrodes are faradaic electrodes.
  • the electrodes are non-faradaic electrodes.
  • a current detector may be used to measure the ionic current through the nanopore and the detected signal may be transmitted to the sequencer controller 1011.
  • a bias is applied across the nanopore 120, a polynucleotide may translocate relative to the nanopore 120.
  • the polypeptide may translocate from the cis well, relative to the nanopore 120, toward the trans well, or vice versa.
  • nucleotide or a sequence combination of nucleotides of the polynucleotide When a nucleotide or a sequence combination of nucleotides of the polynucleotide is in or near the nanopore, it may result in a unique ionic current blockade at the nanopore 120 and, therefore, a unique “nanopore resistance” depending on the identity of the nucleotide or the sequence combination of nucleotides.
  • the polynucleotide translocating relative to the nanopore may modulate the electrical properties of the nanopore such that the nucleobase sequence of the polynucleotide can be identified.
  • the current through the nanopore or the electrical resistance at the nanopore may be a function of the identity of the nucleobase of the polynucleotide at or near the nanopore.
  • the “nanopore resistance” may be different when the polynucleotide is moving through the nanopore in different directions.
  • the target polynucleotide may undergo base pairing during sequencing.
  • the nucleotides utilized for the base pairing may include a unique tag or label.
  • the tag/label may also result in a unique ionic current blockade at the nanopore 120, and thus can be used for sequencing the target polynucleotide.
  • a portion of the polynucleotide may translocate through the nanopore from the cis well toward the trans well, but the polynucleotide as a whole does not exit the nanopore into the trans well.
  • the polynucleotide may translocate through the nanopore from cis well into the trans well.
  • sequencing of a target polynucleotide may involve nanopore sensing of (1) a single-stranded portion of the target polynucleotide; (2) a nucleic acid duplex of a portion of the target poly nucleotide; (3) a label or tag that can be tethered or untethered to the target polynucleotide; (4) chemical modifications thereof, or (5) any combination thereof.
  • multiple nanopore unit cells may be arranged in an array, and each nanopore unit cell may be individually accessed by a logic circuit.
  • a nanopore array may be present in a nanopore sensor device.
  • embodiments herein describe determining a signal level by determining the ionic current through the nanopore, embodiments also include alone or in combination determining the signal level by measuring other electrical characteristics of the nanopore unit cell.
  • a signal level is determined by the voltage potential at a specified area or component of the nanopore cell.
  • a signal level is determined by the conductivity or resistance of the nanopore’s associated membrane.
  • a signal level is determined by the electrical impedance at a specified area or component of the nanopore cell.
  • a nanopore sensor device may have a plurality of nanopore unit cells that forms a sensor array.
  • FIG. 2 depicts an example of a nanopore sensor array 100 that contains a plurality of nanopore unit cells 1000.
  • An example of a nanopore unit cell 1000 is shown in the figure inset.
  • the exemplified nanopore array 100 includes a cis well 12, a cis electrode 14, and a plurality of trans wells 16 separated from the cis well 12 by a polymer/lipid/solid- state/hybrid membrane 18.
  • the membrane 18 contains a plurality of nanopores 20, each associated with a trans well 16 and an individually addressable trans electrode 22.
  • the nanopore(s) 20 may be positioned in, and extend through, the membrane 18 to establish the fluidic connection between the cis well 12 and the trans well(s) 16.
  • the trans wells 16 and the cis well 12 may be filled with an electrolyte solution 24.
  • the trans wells 16 are each associated a trans electrode 22 and are individually addressable.
  • the cis electrode 14 is implemented on the top of the cis well 12. In various embodiments, the width of the cis electrode 14 may be smaller than, larger than or equal to the size of the total or combined widths of the trans wells 16.
  • a bias voltage is applied between the cis electrode 14 and individual trans electrode 22, which can cause flowing the ions in a direction based on the polarity of the applied bias voltage.
  • the negative charged anions (e.g., A-) in the cis well 12 may move toward the nanopore 20 and the trans well 16, thus generating an ionic current flowing from the cis well 12 to the trans well 16.
  • a negative bias voltage e.g., trans electrode 22 has a negative polarity
  • the negative charged anions (e.g., A-) in the trans well 16 moves toward the nanopore 20 and the cis well 12, thus generating an ionic current flowing from the trans well 16 to the cis well 12.
  • the cis electrode 14 that is used depends, at least in part, upon the electrolyte species in the electrolyte solution.
  • the cis electrode 14 may be an active faradaic electrode that takes part in the chemical reaction with an electrochemically active electrolyte species, and can be oxidized or reduced in the half-cell reaction.
  • active electrodes include silver (Ag), copper (Cu), zinc (Zn), lead (Pb), intercalation electrodes (e.g. Prussian blue), redox polymers (e.g. PEDOT), etc.
  • the cis electrode 14 may be an inactive (or inert, or polarizable) electrode that transfers electrons rather than exchanges ions with the electrolyte solution 24.
  • a polarizable electrode may also induce capacitive charging of ions at the electrode-electrolyte interface without directly exchanging ions with the electrolyte solution.
  • inactive electrodes include platinum (Pt), carbon (C) (e.g., graphite, diamond, etc.), gold (Au), rhodium (Rh), etc.
  • the cis electrode 14 may be a silver/silver chloride (Ag/AgCl) electrode.
  • the trans electrode 22 that is used depends, at least in part, upon the electrolyte species in the electrolyte solution.
  • the trans electrode 22 may be an active electrode that takes part in the chemical reaction with an electrochemically active electrolyte species, and can be oxidized or reduced in the half-cell reaction. Any of the examples of the active electrodes set forth herein for the cis electrode 14 may be used as the trans electrode 22.
  • the trans electrode 22 may be an inactive (or inert) electrode that transfers electrons rather than exchanges ions with the electrolyte solution 24. Any of the examples set forth herein for the cis electrode 14 may be used as the trans electrode 22.
  • the trans electrode 22 in the nanopore sensor utilizing an electrolyte solution 24 with an electrically active anion (e.g., chloride, Cl’), the trans electrode 22 may be a silver/silver chloride (Ag/AgCl) electrode.
  • the trans wells 16 are disposed in a hexagonal grid for close packing and improved density.
  • Other layouts may include, for example, rectilinear (i.e., rectangular) layouts, triangular layouts, and so forth.
  • the layout or pattern can be an x-y format of trans wells 16 that are in rows and columns.
  • the layout or pattern can be a repeating arrangement of trans wells 16 and/or interstitial regions 42.
  • the layout or pattern can be a random arrangement of trans wells 16 and/or interstitial regions 42.
  • the pattern may include spots, posts, stripes, swirls, lines, triangles, rectangles, circles, arcs, checks, plaids, diagonals, arrows, squares, and/or cross-hatches.
  • the layout may be characterized with respect to the density of the trans wells 16 (i.e., number of trans wells 16 in a defined area of the substrate 26).
  • the trans wells 16 may be present at a density ranging from about 10 wells per mm 2 to about 1,000,000 wells per mm 2 .
  • the density may be tuned to different densities, including, for example, a density of at least about 10 per mm 2 , about 5,000 per mm 2 , about 10,000 per mm 2 , about 0.1 million per mm 2 , or more.
  • the layout may also or alternatively be characterized in terms of the average pitch, i.e., the spacing from the center of a nanopore 20 to the center of an adjacent nanopore 20 (center-to-center spacing).
  • the pattern can be regular such that the coefficient of variation around the average pitch is small, or the pattern can be non-regular in which case the coefficient of variation can be relatively large.
  • the average pitch may range from about 100 nm to about 500 pm.
  • the average pitch can be, for example, at least about 100 nm, about 5 pm, about 10 pm, about 100 pm, or more.
  • the average pitch can be, for example, at most about 500 pm, about 100 pm, about 50 pm, about 10 pm, about 5 pm, or less.
  • the average pitch for an example array including a particular pattern of nanopores 20 can be between one of the lower values and one of the upper values selected from the ranges above. In an example, the array has an average pitch (center-to-center spacing) of about 10 pm.
  • the trans wells 16 may be micro wells (having at least one dimension on the micron scale, e.g., about 1 pm up to, but not including, 1000 pm), such as from about 1 pm to about 750 pm, such as from about 5 pm to about 500 pm, such as from about 10 pm to about 250 pm, such as from about 15 pm to about 100 pm.
  • Each trans well 16 may be characterized by its aspect ratio (e.g., depth or height divided by width or diameter).
  • the trans wells 16 have an aspect ratio from about 1:10 to about 10:1, from about 1:2 to about 5: 1, or from about 2:3 to about 2: 1 [0121]
  • the depth/height and width/diameter may be selected in order to obtain a desirable aspect ratio.
  • the depth/height of each trans well 16 can be at least about 0.1 pm, about 1 pm, about 10 pm, about 100 pm, or more. Alternatively or additionally, the depth can be at most about 1,000 pm, about 100 pm, about 10 pm, about 1 pm, about 0.1 pm, or less.
  • the width/diameter of each trans well 16 can be at least about 0.1 pm, about 0.5 pm, about 1 pm, about 10 pm, about 100 pm, or more. Alternatively or additionally, the width/diameter can be at most about 1,000 pm, about 100 pm, about 10 pm, about 1 pm, about 0.5 pm, about 0.1 pm, or less.
  • Each trans well 16 has an opening (e.g., that faces the cis well 12) that is large enough to accommodate at least a portion of the membrane 18 and the nanopore 20 that is associated therewith.
  • an end of the nanopore 20 may extend through the membrane 18 and into the opening of the trans well 16.
  • the membrane 18 may be any of the non-permeable or semi-permeable materials described herein.
  • the membrane 18 is positioned between the cis well 12 and the trans wells 16, and thus provides a barrier between the wells 12 and 16.
  • the membrane may be positioned on the interstitial region 42 of the substrate 26.
  • the electrolyte may be any electrolyte that is capable of dissociating into cations and anions.
  • the salt may include any suitable combination of cations (such as, but not limited to, H + , Li + , Na + , K + , NH4 + , Ag + , Ca 2+ ’ Ba 2+ , and/or Mg 2+ ) with any suitable combination of anions (such as, but not limited to, OH', Cl', Br', I', NCb', ClOF, F', SO4 2 ', and/or CO? 2 '.).
  • the electrolyte can be for an Ag/AgCl redox system.
  • the electrolyte may also be one or more salts of a a redox mediator system, such as ferrocyanide/ferricyanide redox couple in an electrolyte buffer in which ferrocyanide ions (e.g., Fe(CN)e 4 ') are oxidized to ferricyanide ions (e.g., Fe(CN)e 3 ') and ferricyanide ions (Fe(CN)e 3 ') are reduced to ferrocyanide ions (Fe(CN)e 4 ').
  • the mediator system may be combined with a secondary electrolyte species (e.g., KC1). It is believed that O-company uses ferrocyanide/ferricyanide.
  • the nanopore sensor device 100 also includes electronics to individually and/or collectively address each of the trans electrodes 22.
  • each of the trans electrodes 22 is associated with a respective trans well 16 and a respective nanopore 20.
  • the electronics include at least a stimulus source and a controller.
  • a function generator 19 is applied to a common cis electrode 14 for a plurality of trans wells 16.
  • each of the trans electrodes comprises electronics 17 to individually address each of the trans electrodes 22 by applying a waveform and by individually measuring a signal from the trans electrode.
  • a controller 23 is coupled to the function generator 19 and the electronics 17 to control current flow through an individual nanopore 20 by addressing an individual trans electrodes 22.
  • the controller is coupled to the stimulus source, and the controller is configured to individually/selectively address one of the plurality of trans electrodes 22 (using the stimulus source) to cause an ionic current to flow through the nanopore 20 connected to the addressed trans electrode 22.
  • the electronics may also include amplifier(s) to amplify electrical signals passing through respective nanopores 20 associated with trans electrodes 22 that are addressed.
  • the stimulus source applies a voltage bias between the cis well 12 and at least one of the plurality of trans wells 16 (using the electrodes 14, 22), and thus across the nanopore 20 and the membrane 18.
  • the voltage bias that is applied may be a positive polarity to the trans electrode 22 to attract negative charge compounds (such as negatively charge nucleotides, negatively charged labels/tags) in the cis well 12 towards the nanopore 20 and/or a negative polarity to the trans electrode 22 to repel negatively charged compounds (such as negatively charge nucleotides, negatively charged labels/tags) in the cis well 12 away from the nanopore 20.
  • the voltage bias ranges from about -10 V to about 10 V, from about -5 V to about 5 V, from about -2 V to about 2 V, or from about -1 V to about 1 V between the cis electrode 14 and the trans electrodes 22 during a sensing or sequencing cycle. Any voltage bias within the given range may be applied during a sensing or sequencing cycle.
  • the voltage bias when measuring nucleobase identities (sequencing phase), the voltage bias may range from about -200 mV to about 200 mV; during nonmeasurement, such as ejection, capturing or recharging phases (which will be explained in more details below), the voltage bias may range from about 0 mV to about 500 mV, or from about -1000 mV to about 1000 mV in various phases.
  • the nanopore sensor device 100 operates in a bipolar mode (e.g., alternating current), providing a negative bias and a positive bias to the trans electrode 22.
  • the nanopore sensor device 100 operates in a unipolar mode (e.g., direct current), providing a negative bias to the trans electrode 22.
  • the voltage can be reduced, or the polarity reversed, to facilitate appropriate function.
  • an external (i.e., off the chip) cis electrode as part of a microfluidics setup while having sensing electrodes/trans electrodes addressing each nanopore embedded in the chip.
  • the cis electrode can be places several centimeters from the chip surface.
  • the actual voltage difference across a nanopore is not the same as the voltage applied between the cis electrode and the nanopore’s corresponding trans electrode, because the electrolyte connection between the cis electrode and the nanopore has a non- zero electrical resistance.
  • the electrolyte connection between the cis electrode and the nanopores has a resistance Rs (i.e., series resistance or solution resistance) that may depend on factors such as salt concentration and the length and the diameter of the fluidics connection between the electrode and the chip surface.
  • the actual voltage difference across a nanopore would depend on Rs and further on the “nanopore resistances” that relate to how easily ions can go through the nanopore unit cells given the states of the membranes, pore proteins and polynucleotides in or near the nanopores.
  • FIG. 3 A illustrates an equivalent circuit diagram of the nanopore device 100 as depicted in FIG. 2.
  • the total resistance Rptot in a large array can be orders of magnitude smaller than that of single or few unit cell. For example, an array of 100,000 nanopore unit cells where each individual nanopore unit cell features a resistance of IGOhm would have a total resistance of only lOkOhm. For large enough arrays of nanopore unit cells, the total resistance of all nanopore unit cells can therefore become comparable to the resistance of the electrolyte connection leading to the cis electrode.
  • Vbias 126 is applied to the cis electrodel4
  • Vois be controlled to within about within about 0.1 mV, within about 1 mV, or within about 5 mVof a desired value.
  • Is is also the sum of the currents going through each individual nanopore unit cells, any change in the total current Is is reflected in a shift in Vs and therefore a change in the Vois applied to the cis end of the nanopores.
  • Changes of the total current in the system can occur in multiple ways. For example, it may be necessary to turn off a nanopore sensor during a sequencing run if the membrane supporting the nanopore breaks, or if multiple pores are present in a membrane for an individual trans well. When the total number of active channels is reduced in this way the total resistance of the system increases and thus causing the total current to decrease. In some instances, a sensor’s bias voltage may need to be changed independently for a particular stage of the sequencing process.
  • individual sensors can be set to a number of different voltages to enable ejection of a used (i.e., completed sequencing) or stalled polynucleotide from a nanopore, replenishing of electrochemical components inside a cis/trans well, or capturing of a fresh polynucleotide in the nanopore.
  • a used i.e., completed sequencing
  • the current going through the respective pore can become larger, smaller, and even opposite in sign to the typical current observed in the sequencing mode.
  • electrolyte may be depleted due to different ionic species being transported across the nanopore at different rates, which can cause a shift in electrolyte composition in the sensor’s trans well.
  • the current may also change due to intrinsic pore noise that is in part induced by fast conformational changes of the pore protein.
  • Different polynucleotide sequences also cause specific changes in the pore resistance (and thus observed pore current) as the polynucleotide translocate relative to the nanopore.
  • different number of nanopores may be present in the array between setups. Loading the individual channels/wells with nanopores is related to the fluid concentration of nanopores that is subject to process variations, which leads to pore insertion in fewer than all of the desired individual channels/wells. While a pore resistance during a run may not be significantly affected by a neighboring channel/well without an inserted pore, the variability of pore insertion may be accounted for in order to control Vois.
  • FIG. 3B is showing the effect on Vois in response to a 10% change in Rptot for different ratios of Rptot/Rs.
  • the current Is may be minimized by balancing the current between neighboring channels in the nanopore array and by mitigating the adverse voltage drop effect across the fluidic line.
  • certain embodiments provide achieving a net- zero or near-zero electrical current flow through the nanopore array. This may be accomplished by controlling the state of nanopore unit cells to achieve zero net current flow. For example, as illustrated in FIG. 4, the currents in different unit cells differ in magnitudes and directions, such that the sum of currents is approximately zero. As a result, when the total net current flowing through the nanopores is zero or close to zero, the voltage drop Vs is zero or close to zero and thus the voltage difference applied to the nanopores can be known to a greater precision (i.e., equal or close to Vbias-Vtrans,i).
  • a unit cell with an open well where no membrane was formed, a unit cell with a burst or non-intact membrane, a unit cell with an intact membrane where no nanopore was formed, a unit cell with a membrane having an open nanopore without an analyte, and/or a unit cell with a membrane having multiple nanopores is used to balance currents in the array of nanopore unit cells to achieve net-zero or near-zero current.
  • nanopore unit cells in these states may be applied with a reverse current (e.g., used for recharging) opposite to a forward current (e.g., used for sequencing) applied to a nanopore unit cell with a membrane having a nanopore in which a polynucleotide is inserted.
  • a reverse current e.g., used for recharging
  • a forward current e.g., used for sequencing
  • a controller such as controller 1011 of FIG. 1A, of the instrument calculates the amount of current consumed over time to determine which wells/electrodes to apply a forward or reverse current.
  • the controller may be a FPGA.
  • the nanopore device correlates the measured electrical characteristics with the sequencing process.
  • the current flow direction can correspond to the stages of the sequencing process. For example, as shown in FIG. 5A, when a positive bias is applied at the trans electrode relative to the cis electrode, anions can flow from the cis well to the trans well, which creates a “forward current.” A polynucleotide, being negatively charged, is also attracted to the positively biased trans electrode and moves from the cis well towards the trans well. This causes the polynucleotide to translocate relative to the nanopore towards the trans well.
  • anions can flow from the trans well into the cis well.
  • the negatively charged polynucleotide is repelled by the negatively biased trans electrode and results in translocation of the polynucleotide relative to the nanopore away from the trans wells. This direction can generally be referred to as a “reverse current.”
  • the nanopore when the nanopore may be an open nanopore without a captured polynucleotide, the ionic concentrations in the cis and the trans wells may be rebalanced by negatively biasing the trans electrode to provide a reverse current moving anions from the trans well into the cis well.
  • the nanopore may have an analyte (e.g., polynucleotide) in it.
  • a positive bias is applied at the trans electrode to provide a forward current and to capture the polynucleotide by the nanopore of the trans well.
  • no polynucleotide is captured by a nanopore which is inserted in a membrane; this situation is termed an “open pore” state and is associated with either a forward or a reverse current, depending on the polarity of the difference between Vtrans and Vois.
  • no nanopore is inserted in the membrane and thus no current can flow through the unit cell. If the magnitude of (Vtrans and Vois) increases beyond a threshold value, the membrane may break (or rupture or burst).
  • certain embodiments provide a nanopore device with a net- zero or near net-zero current scheme that can minimize the total current in the nanopore array.
  • the net-zero or near net-zero total current can be achieved by balancing the amount of forward current and reverse current from all the nanopore unit cells in the array.
  • the nanopore device determines the electrical characteristics of each nanopore unit cell to infer its state. For example, the forward current flows when the state is sequencing or capturing a polynucleotide, and the reverse current flows when the state is recharging and/or ejection.
  • the nanopore device can balance the currents in the nanopore unit cells to achieve the net- zero or near net-zero total current or charge to replenish the redox mediators within the nanopore cells or restore the balance of redox mediators (e.g., ferrocyanide and ferricyanide) in the trans well.
  • redox mediators e.g., ferrocyanide and ferricyanide
  • the system can change the state of two nanopore unit cells into recharging.
  • the sum of currents in the two recharging nanopore unit cells can compensate the sum of currents in the other eight nanopore unit cells, the total current in these ten nanopore unit cells is zero or near zero.
  • changing the state for each nanopore unit cell can be performed by implementing a circuitry configured to control the state.
  • the state for example, can include sequencing, ejecting, recharging, and capturing.
  • the circuitry can be utilized to perform the controlling scheme of the nanopore device. For example, during the sequencing and/or capturing states, the circuitry may generate positive bias voltage meaning that the voltage that enables the potential at trans wells is higher than the cis well. In another example, during the ejecting and/or recharging states, the circuitry may generate a negative bias to enable the cis well to have a higher potential than the trans well.
  • the magnitude of the potential difference in each state can also be varied, such that the recharging state can have a higher magnitude than the sequencing state.
  • the first waveform can be applied to a first subset of nanopores and the second waveform can be applied to a second subset of nanopores.
  • the first subset of nanopores can have positive bias voltage and provides forward current
  • the second subset of nanopores can have reverse bias voltage and provides reverse current.
  • FIG. 6A illustrates one example scheme of balancing currents to achieve net-zero of near zero total current in the nanopore array.
  • the system determined the state of each nanopore cell of the nanopore array, where the state may be one of:
  • the system then individually applied waveforms to two sub-sets of the nanopore cells so that the net current was approximately zero, where the two subsets were:
  • Subset (1) Sequencing of captured DNA/strand template. Two example sequencing processes used in conjunction with this scheme were described in U.S. Patent Application Nos. 17/933,833 and 18/311,876.
  • Subset (2) Recharging of open pore or blocked pore [0150]
  • the system may repeat the first step and the second step at the end of the second step, or after a portion of the waveform’s period.
  • FIG. 6B illustrates one example scheme of balancing currents to achieve net-zero of near zero total current in the nanopore array.
  • the system determined the state of each nanopore cell of the nanopore array, where the state may be one of:
  • the system then individually applied waveforms with positive bias or negative bias to sub-sets of the nanopore cells (via the trans electrodes) so that the net current was approximately zero, where the subsets were:
  • Subset (1) Sequencing of captured DNA/strand template. Two example sequencing processes used in conjunction with this scheme were described in U.S. Patent Application Nos. 17/933,833 and 18/311,876. This subset will be applied with positive potential on their trans electrodes.
  • Subset (2) Capture of DNA strand/template. This subset will be applied with positive potential on their trans electrodes.
  • Subset (3) Combinations of (1) and (2). This subset will be applied with positive potential on their trans electrodes.
  • Subset (4) Recharging of open pore. This subset will be applied with negative potential on their trans electrodes.
  • Subset (5) Ejection of the DNA strand/template. This subset will be applied with negative potential on their trans electrodes.
  • Subset (6) Combinations of (4) and (5). This subset will be applied with negative potential on their trans electrodes.
  • the system may repeat the first step and the second step at the end of the second step, or after a portion of the waveform’s period.
  • FIG. 7A, FIG. 7B and FIG. 7C illustrate some example schemes of balancing currents to achieve net-zero of near zero total current in the nanopore array.
  • the system individually applied AC e.g., sinusoidal waveforms to two or more subsets of the nanopore cells so that the net current is approximately zero.
  • FIG. 7A illustrates that two waveforms 180 degrees out of phase were applied to two subsets of the nanopore cells.
  • FIG. 7B illustrates that three waveforms 120 degrees out of phase were applied to three subsets of the nanopore cells.
  • FIG. 7C illustrates that four waveforms 90 degrees out of phase were applied to four subsets of the nanopore cells.
  • Embodiments can include also unhealthy unit cells (multiple pores inserted into the membrane of a unit cell) and open wells (ruptured membrane in a unit cell) as control mechanism or even rupturing on purpose leading to more open wells to have more current flow and thus balancing capacity available.
  • Either open pore currents or even an external probe may be used as a measure of the voltage bias variability. Calculating the currents on a per channel basis is another embodiment to knowing the sum of current passing in each direction. For example, net current measurements can be done by monitoring the current on the cis electrode, or by measuring open pore currents and inferring bias drifts from that (e.g., and then concluding that net current is zero when the bias drop across the buffer is zero and therefore the open pore current is within specified bounds).
  • the needed sum of negative currents would be inferred at each stage of the sequencing process, as illustrated by FIG. 8.
  • the unit cells going into the capturing state would be limited based on the imbalanced current allowed and available current flow capacity (open wells, creating open wells from unhealthy open pores and open pores which are not capturing). If zero imbalanced currents is allowed (which means at all times the net current needs to be zero which limits the active channels depending on the available current flow capacity), that limit would not be there as a little current flow in one direction would be allowed for some time, maybe up to one full sequencing run on a number of cells, and then current balancing can be achieved additionally by coordinating the states with other cells.
  • it requires recharging on a per unit cell basis so that the open wells would not deplete for a future run, which could be done with the recharging step.
  • a charge counter for all unit cells and an array net charge counter are needed, while a current measurement is not needed (but still would be helpful for precise data or faster reaction time as opposed to a software estimate).
  • the workflows need to be actively summing all unit cells’ currents and adjust the counter currents within a time frame given by the allowed net current for safe sequencing.
  • the initial state of the nanopore array needs to be considered to determine how many unit cells can start to capture polynucleotides for sequencing, since the first, capturing state is the one with the most net current due to the high voltage the capturing applies and the low resistance without template. So, if the ratio of open wells/open pores is such that it can balance the capturing channels, then all other states afterward are within that scenario and boundaries because capturing is the most current intense state.
  • ranges provided herein include the stated range and any value or sub-range within the stated range, as if such value or sub-range were explicitly recited.
  • a range from about 2 nm to about 20 nm should be interpreted to include not only the explicitly recited limits of from about 2 nm to about 20 nm, but also to include individual values, such as about 3.5 nm, about 8 nm, about 18.2 nm, etc., and sub-ranges, such as from about 5 nm to about 10 nm, etc.
  • “about” and/or “substantially” are/is utilized to describe a value, this is meant to encompass minor variations (up to +/- 10%) from the stated value.
  • Conditional language such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain examples include, while other examples do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more examples or that one or more examples necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular example.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Systems and methods for nanopore sequencing are disclosed. The systems and methods are related to implementing a net-zero or near-zero current scheme of an array of nanopore unit cells. In one example, the system includes an array of nanopore unit cells, a cis well, a cis electrode, an application specific integrated circuit (ASIC) layer with active circuitries, and a processor. The processor can be configured to characterize each state of the nanopore unit cell and control the individual nanopore unit cells to achieve net-zero or near-zero total current in the array of nanopores.

Description

NET-ZERO CURRENT SCHEME FOR NANOPORE SYSTEM
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63/552,562, filed February 12, 2024, the content of which is incorporated by reference in its entirety.
BACKGROUND
Field
[0002] The present technology generally relates to devices for determining the sequence of a biopolymer, such as a polynucleotide or polypeptide, and more specifically to nanopore sequencing devices.
Description of the Related Art
[0003] Various polynucleotide sequencing techniques involve performing a large number of controlled reactions on support surfaces or within predefined reaction chambers. The controlled reactions may then be observed or detected, and subsequent analysis may help identify the properties of the polynucleotide involved in the reaction. Examples of such sequencing techniques include next-generation sequencing or massive parallel sequencing involving sequencing-by-ligation, sequencing-by-synthesis, reversible terminator chemistry, or pyrosequencing approaches.
[0004] Some polynucleotide sequencing techniques utilize a nanopore, which can provide a path for an ionic current. For example, as the polynucleotide traverses through the nanopore, it influences the ionic current through the nanopore. Each nucleotide, or series of nucleotides, that translocates relative to the nanopore yields a characteristic electrical signal. These characteristic electrical signals, as a result of the traversing polynucleotide, can be recorded to determine the sequence of the polynucleotide. However, library preparation, devices, systems, methods, and/or software involved in nanopore sequencing still lack robustness, reproducibility, sensitivity, and/or accuracy.
SUMMARY
[0005] Provided herein are devices and method for sequencing biopolymers such as polynucleotides and polypeptide.
[0006] The devices and methods disclosed herein each have several aspects, no single one of which is solely responsible for their desirable attributes. Without limiting the scope of the claims, some prominent features will now be discussed briefly. Numerous other examples are also contemplated, including examples that have fewer, additional, and/or different components, steps, features, objects, benefits, and advantages. The components, aspects, and steps may also be arranged and ordered differently. After considering this discussion, and particularly after reading the section entitled “Detailed Description,” one will understand how the features of the devices and methods disclosed herein provide advantages over other known devices and methods.
[0007] Embodiment 1. A method of generating net- zero or near-zero current scheme in an array of nanopore unit cells, the method comprising:
[0008] determining a state of an nanopore unit cell of the array of nanopore unit cells; and
[0009] applying a waveform to the nanopore unit cell based at least on the determined state of the nanopore unit cell.
[0010] Embodiment 2. The method as defined in Embodiment 1 , wherein the states comprise: a unit cell with an open well where no membrane was formed, a unit cell with a burst or non-intact membrane, a unit cell with an intact membrane where no nanopore was formed, a unit cell with a membrane having an open nanopore without an analyte, a unit cell with a membrane having a nanopore in which an analyte is inserted, or a unit cell with a membrane having multiple nanopores.
[0011] Embodiment 3. The method as defined in Embodiment 1, wherein a unit cell with an open well where no membrane was formed, a unit cell with a burst or nonintact membrane, a unit cell with an intact membrane where no nanopore was formed, a unit cell with a membrane having an open nanopore without an analyte, and/or a unit cell with a membrane having multiple nanopores is used to balance currents in the array of nanopore unit cells to achieve net-zero or near-zero current.
[0012] Embodiment 4. The method as defined in Embodiment 1 , comprising:
[0013] dividing the array of nanopore unit cells into sub-groups based at least on the determined state of each individual nanopore unit cell; and
[0014] applying a waveform to each sub-group.
[0015] Embodiment 5. The method as defined in Embodiment 4, wherein the sub-groups comprise sequencing, ejecting, recharging, and capturing.
[0016] Embodiment 6. The method as defined in Embodiment 5, wherein the sequencing and capturing sub-groups are associated with forward currents, and wherein the ejecting and recharging sub-groups are associated with reverse currents.
[0017] Embodiment 7. The method as defined in Embodiment 1 , comprising determining the state of an individual nanopore unit cell based on the magnitude and/or direction of the current flowing through the individual nanopore unit cell.
[0018] Embodiment s. The method as defined in Embodiment 1, further comprising, in response to determining that total current of the array is not zero or is above a predetermined threshold, changing the state of at least one nanopore unit cell to change the magnitude and/or direction a corresponding current.
[0019] Embodiment 9. The method as defined in Embodiment 1 , further comprising determining waveforms to be applied to nanopore unit cells in the array to achieve net-zero or near- zero total current of the array by a FPGA.
[0020] Embodiment 10. The method as defined in Embodiment 1, wherein the waveform applied to at least one nanopore unit cell is AC.
[0021] Embodiment 11. The method as defined in Embodiment 10, wherein the AC waveforms applied to at least two of the nanopore unit cells have different phases.
[0022] Embodiment 12. The method as defined in Embodiment 4, wherein a first and second sub-groups are determined, wherein nanopore unit cells included in the first subgroup have forward currents, and wherein nanopore unit cells included in the second sub-group have reverse currents. [0023] Embodiment 13. The method as defined in Embodiment 1, further comprising monitoring the total current of the array of nanopore unit cells.
[0024] Embodiment 14. The method as defined in Embodiment 4, further comprising, in response to determining that the total current is not zero or is above a predetermined threshold, re-dividing the array of nanopore unit cells.
[0025] Embodiment 15. The method as defined in Embodiment 4, wherein assigning nanopore unit cells to each sub-groups is based at least on a conductivity associated with the individual nanopore unit cells.
[0026] Embodiment 16. A nanopore device, comprising:
[0027] an array of nanopore unit cells, each unit cell having a trans well at the bottom of the unit cell;
[0028] an application specific integrated circuit (ASIC) layer disposed below the array of nanopore unit cells, wherein the ASIC layer comprises an array of active circuitries; and
[0029] a processor, the processor configured to:
[0030] determine a state of a nanopore unit cell of the array; and
[0031] control the state of the individual nanopore unit cell.
[0032] Embodiment 17. The nanopore device as defined in Embodiment 16, further comprising:
[0033] a cis well and an associated cis electrode on top of the array of nanopore unit cells.
[0034] Embodiment 18. The nanopore device as defined in Embodiment 16, wherein an electrolyte solution is filled in the cis well.
[0035] Embodiment 19. The nanopore device as defined in Embodiment 16, further comprising:
[0036] a trans electrode, wherein the trans electrode is disposed in an individual trans well, and wherein the trans electrode is electrically connected with a corresponding active circuitry in the ASIC.
[0037] Embodiment 20. The nanopore device as defined in Embodiment 16, wherein the state comprises an open well where no membrane was formed, an intact membrane where no nanopore was formed, a membrane with an open nanopore without an analyte, a membrane with a nanopore in which an analyte is inserted, or a membrane with multiple nanopores.
[0038] Embodiment 21. The nanopore device as defined in Embodiment 16, wherein the processor is configured to determine the state of a nanopore unit cell based on the magnitude and/or direction of the current flowing through the cell.
[0039] Embodiment 22. The nanopore device as defined in Embodiment 16, wherein the processor is configured to change the states of at least one nanopore unit cell in response to determining that the net current of the array is not zero or is above a predetermined threshold magnitude.
[0040] Embodiment 23. The nanopore device as defined in Embodiment 16, wherein the processor is further configured to determine waveforms which can achieve net- zero or near-zero total current in the array of nanopore unit cells.
[0041] Embodiment 24. The nanopore device as defined in Embodiment 23, wherein the waveforms applied to at least two of the nanopore unit cells have a different phases.
[0042] Embodiment 25. The nanopore device as defined in Embodiment 16, wherein the processor is a FPGA.
[0043] Embodiment 26. The nanopore device as defined in Embodiment 19, wherein the voltage applied to each individual trans electrode is independently controlled.
[0044] It is to be understood that any features of the device and/or of the array disclosed herein may be combined together in any desirable manner and/or configuration. Further, it is to be understood that any features of the method of using the device may be combined together in any desirable manner. Moreover, it is to be understood that any combination of features of this method and/or of the device may be used together and/or may be combined with any of the examples disclosed herein. Still, further, it is to be understood that any feature or combination of features of any of the devices and/or of the arrays and/or of any of the methods may be combined together in any desirable manner and/or may be combined with any of the examples disclosed herein.
[0045] It should be appreciated that all combinations of the foregoing concepts and additional concepts discussed in greater detail below are contemplated as being part of the inventive subject matter disclosed herein and may be used to achieve the benefits and advantages described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Features of examples of the present disclosure will become apparent by reference to the following detailed description and drawings, in which like reference numerals correspond to similar, though perhaps not identical, components. For the sake of brevity, reference numerals or features having a previously described function may or may not be described in connection with other drawings in which they appear.
[0047] FIG. 1A illustrates one embodiment of a nanopore sequencing system.
[0048] FIG. IB illustrates a portion of one of the nanopore unit cells of the example nanopore sequencing system of FIG. 1A.
[0049] FIG. 2 illustrates a cross-sectional view of one embodiment a nanopore sensor device.
[0050] FIG. 3A illustrates an equivalent circuit diagram of the nanopore sensor device of FIG. 2. FIG. 3B shows effects on Vois in response to changes in Rptot.
[0051] FIG. 4 illustrates the current flows in nanopore unit cells in a net-zero current scheme.
[0052] FIG. 5A depicts the different modes of operation in a nanopore unit cell during an example course of sequencing. FIG. 5B shows an example waveform that may be used in connection with some modes depicted in FIG. 5A.
[0053] FIG. 6A illustrates one example scheme of balancing currents to achieve net-zero or near zero total current in the nanopore array.
[0054] FIG. 6B illustrates one example scheme of balancing currents to achieve net-zero or near zero total current in the nanopore array.
[0055] FIG. 7A, FIG. 7B and FIG. 7C illustrate some example schemes of balancing currents to achieve net- zero or near zero total current in the nanopore array.
[0056] FIG. 8 shows an example of current ratios between various states that can achieve a net- zero current scheme.
[0057] FIG. 9 shows an example of current ratios between various states that can achieve a net- zero current scheme. DETAILED DESCRIPTION
[0058] All patents, applications, published applications, and other publications referred to herein are incorporated herein by reference to the referenced material and in their entirety. If a term or phrase is used herein in a way that is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications, and other publications that are herein incorporated by reference, the use herein prevails over the definition that is incorporated herein by reference.
Definitions
[0059] All technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs unless clearly indicated otherwise.
[0060] As used herein, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a sequence” may include a plurality of such sequences, and so forth.
[0061] The terms comprising, including, containing and various forms of these terms are synonymous with each other and are meant to be equally broad. Moreover, unless explicitly stated to the contrary, examples comprising, including, or having an element or a plurality of elements having a particular property may include additional elements, whether or not the additional elements have that property.
[0062] As used herein, the term “electric connection” and the like refer to two spatial regions being connected together such that electrons, holes, ions or other charge carriers may flow between the two spatial regions.
[0063] If an electrolyte flows between two connected wells, ionic current may also flow between the connected wells. In some examples, two spatial regions may be in fluid/ionic/electric communication through one or more nanoscale openings or through one or more valves, restrictors, or other fluidic components that are to control or regulate a flow of fluid, ionic current through a system.
[0064] As used herein, the term “operably connected” refers to a configuration of elements, wherein an action or reaction of one element affects another element, but in a manner that preserves each element's functionality. [0065] As used herein, the term “membrane” refers to a non-permeable or semi- permeable barrier or other sheet that separates two liquid/gel chambers (e.g., a cis well and a trans well) which can contain the same compositions or different compositions therein. Any membrane may be used in accordance with the present disclosure, as long as the membrane can include a transmembrane nanoscale opening and can maintain a potential difference across the membrane. The membrane may be a monolayer or a multilayer membrane. A multilayer membrane includes two or more layers. The membrane may be formed of materials of non- biological or biological origin.
[0066] An example membrane that is made from non-biological materials are block copolymer. The term is a “block copolymer” is intended to refer to a polymer having at least a first portion or block that includes a first type of monomer, and at least a second portion or bloc” that is coupled directly or indirectly to the first portion and includes a second, different type of monomer. Block copolymers include, but are not limited to, diblock copolymers and triblock copolymers. A “diblock copolymer” is intended to refer to a block copolymer that includes a first and second blocks coupled directly or indirectly to one another. The first block may be hydrophilic and the second block may be hydrophobic, in which case the diblock copolymer may be referred to as an “AB” copolymer where “A” refers to the hydrophilic block and “B” refers to the hydrophobic block. A “triblock copolymer” is intended to refer to a block copolymer that includes a first, second, and third blocks coupled directly or indirectly to one another. The first and third blocks may include, or may consist essentially of, the same type of monomer (repeating unit) as one another, and the second block may include a different type of monomer (repeating unit). In one example, the first block may be hydrophilic, the second block may be hydrophobic, and the third block may be hydrophilic and includes the same type of monomer as the first block, in which case the triblock copolymer may be referred to as an “ABA” copolymer where “A” refers to the hydrophilic blocks and “B” refers to the hydrophobic block. The block copolymers may be formed into a bilayer membrane in which the hydrophilic blocks are positioned on the outward of the bilayer membrane and in which the hydrophobic blocks are positioned inward of the bilayer membrane.
[0067] Example hydrophilic A blocks include, but are not limited to, a polymer selected from the group consisting of: N-vinyl pyrrolidone, polyacrylamide, zwitterionic polymer (Zwitt), hydrophilic polypeptide, poly(ethylene glycol) (PEG), carbon-oxygen- nitrogen containing polymers (CxOyNZ), polyacrylic acid, and combinations thereof. Example hydrophobic B blocks inlclude, but are not limited to, poly(dimethylsiloxane) (PDMS), poly(isobutylene) (PiB), polybutadiene (PBd), polyisoprene, polymyrcene, polychloroprene, hydrogenated polydiene, polystyrene, fluorinated polyethylene, polypeptide, and combination thereof. Example block copolymers used to form a bilayer membrane include, but are not limited to, PDMS-a/?-Zwitt, PiB-a/?-Zwitt, PiB-a/?-PEG, PiB-a/>-(CxOyNz), PDMS-a/?-PEG, PDMS-a/>-(CxOyNz), PiB-a/?a-Zwitt, PiB-a/?a-PEG, PiB-a/>a-(CxOyNz), and PDMS-a/?a- PEG, PDMS-a/>-(CxOyNz), and other suitable block copolymers,
[0068] An example membrane that is made from non-biological materials are solid- state materials. The solid-state membrane can be a monolayer, such as a coating or film on a supporting substrate (i.e., a solid support), or a freestanding element. The solid-state membrane can also be a composite of multilayered materials in a sandwich configuration. Any material not of biological origin may be used, as long as the resulting membrane can include a transmembrane nanoscale opening and can maintain a potential difference across the membrane. The membranes may include organic materials, inorganic materials, or both. Examples of suitable solid-state materials include, for example, microelectronic materials, insulating materials (e.g., silicon nitride (SisNA), aluminum oxide (AI2O3), hafnium oxide (HfCh), tantalum pentoxide (Ta2Os), silicon oxide (SiCh), etc.), some organic and inorganic polymers (e.g., polyamide, plastics, such as polytetrafluoroethylene (PTFE), or elastomers, such as two-component addition-cure silicone rubber), and glasses. In addition, the solid-state membrane can be made from a monolayer of graphene, which is an atomically thin sheet of carbon atoms densely packed into a two-dimensional honeycomb lattice, a multilayer of graphene, or one or more layers of graphene mixed with one or more layers of other solid-state materials. A graphene-containing solid-state membrane can include at least one graphene layer that is a graphene nanoribbon or graphene nanogap, which can be used as an electrical sensor to characterize the target polynucleotide. It is to be understood that the solid-state membrane can be made by any suitable method, for example, chemical vapor deposition (CVD). In an example, a graphene membrane can be prepared through either CVD or exfoliation from graphite. [0069] As used herein, “synthetic” refers to a membrane material that is not of biological origin (e.g., polymeric materials, synthetic phospholipids, solid-state membranes, or combinations thereof).
[0070] A synthetic phospholipid bilayer can be formed, for example, from two opposing layers of phospholipids, which are arranged such that their hydrophobic tail groups face towards each other to form a hydrophobic interior, whereas the hydrophilic head groups of the lipids face outwards towards the aqueous environment on each side of the bilayer. Lipid bilayers also can be formed, for example, by a method in which a lipid monolayer is carried on an aqueous solution/air interface past either side of an aperture that is substantially perpendicular to that interface. The lipid is normally added to the surface of an aqueous electrolyte solution by first dissolving it in an organic solvent and then allowing a drop of the solvent to evaporate on the surface of the aqueous solution on either side of the aperture. Once the organic solvent has at least partially evaporated, the solution/air interfaces on either side of the aperture are physically moved up and down past the aperture until a bilayer is formed. Other suitable methods of bilayer formation include tip-dipping, painting bilayers, and patchclamping of liposome bilayers. Any other methods for obtaining or generating lipid bilayers may also be used.
[0071] As used herein, the term “nanopore” is intended to mean a hollow structure discrete from, or defined in, and extending across the membrane. The nanopore permits ions, electric current, and/or fluids to cross from one side of the membrane to the other side of the membrane. For example, a membrane that inhibits the passage of ions or water-soluble molecules can include a nanopore structure that extends across the membrane to permit the passage (through a nanoscale opening extending through the nanopore structure) of the ions or water-soluble molecules from one side of the membrane to the other side of the membrane. The diameter of the nanoscale opening extending through the nanopore structure can vary along its length (i.e., from one side of the membrane to the other side of the membrane), but at any point is on the nanoscale (i.e., from about 1 nm to about 100 nm, or to less than 1000 nm). Examples of the nanopore include, for example, biological nanopores, solid-state nanopores, and biological and solid-state hybrid nanopores. In some embodiments, a nanopore refers to a pore having an opening with a diameter at its most narrow point of about 0.3 nm to about 2 nm. For example, a nanopore may be a solid-state nanopore, a graphene nanopore, an elastomer nanopore, or may be a naturally-occurring or recombinant protein that forms a tunnel upon insertion into a bilayer, thin film, membrane, or solid-state aperture, also referred to as a protein pore or protein nanopore herein (e.g., a transmembrane pore). If the protein inserts into the membrane, then the protein is a tunnel-forming protein.
[0072] As used herein, the term “diameter” is intended to mean a longest straight line inscribable in a cross-section of a nanoscale opening through a centroid of the crosssection of the nanoscale opening. It is to be understood that the nanoscale opening may or may not have a circular or substantially circular cross-section. Further, the cross-section may be regularly or irregularly shaped.
[0073] As used herein, the term “biological nanopore” is intended to include, for example, polypeptide nanopores and polynucleotide nanopores. The polypeptide nanopores and polynucleotide nanopores may include portions that are wild-type, mutants, engineered, and combinations thereof.
[0074] As used herein, the term “polypeptide nanopore” is intended to mean a protein/polypeptide that extends across the membrane, and permits ions, electric current, polymers such as DNA or peptides, or other molecules of appropriate dimension and charge, and/or fluids to flow therethrough from one side of the membrane to the other side of the membrane. A polypeptide nanopore can be a monomer, a homopolymer, or a heteropolymer. Structures of polypeptide nanopores include, for example, an a-helix bundle nanopore and a P-barrel nanopore. Example polypeptide nanopores include a-hemolysin, Mycobacterium smegmatis porin A (MspA), gramicidin A, maltoporin, OmpF, OmpC, PhoE, Tsx, F-pilus, aerolysin, CsgG, etc. The protein a-hemolysin is found naturally in cell membranes, where it acts as a pore for ions or molecules to be transported in and out of cells. Mycobacterium smegmatis porin A (MspA) is a membrane porin produced by Mycobacteria, which allows hydrophilic molecules to enter the bacterium. MspA forms a tightly interconnected octamer and transmembrane beta-barrel that resembles a goblet and contains a central pore.
[0075] A polypeptide nanopore can be non-natural. A non-natural polypeptide nanopore includes a protein-like amino acid sequence that does not occur in nature. The protein-like amino acid sequence may include some of the amino acids that are known to exist but do not form the basis of proteins (i.e., non-proteinogenic amino acids). The protein-like amino acid sequence may be artificially synthesized rather than expressed in an organism and then purified/isolated.
[0076] As used herein, the term “polynucleotide nanopore” is intended to include a polynucleotide that extends across the membrane, and permits ions, ionic current, and/or fluids to flow from one side of the membrane to the other side of the membrane. A polynucleotide pore can include, for example, a polynucleotide origami (e.g., nanoscale folding of DNA to create the nanopore).
[0077] As used herein, the term “solid-state nanopore” is intended to mean a nanopore whose structure portion is defined by a solid-state membrane. A solid-state nanopore can be formed of an inorganic or organic material. Solid-state nanopores include, for example, silicon nitride nanopores, silicon dioxide nanopores, solid-state nanopores in polymeric membranes (e.g., polyimide), and graphene nanopores.
[0078] The nanopores disclosed herein may be hybrid nanopores. A “hybrid nanopore” refers to a nanopore including materials of both biological and non-biological origins. An example of a hybrid nanopore includes a polypeptide-solid-state hybrid nanopore and a polynucleotide-solid-state nanopore.
[0079] The application of the potential difference across a nanopore may force the translocation of a nucleic acid or a polynucleotide through or relative to the nanopore. One or more signals are generated that correspond to the translocation of the nucleotide through or relative to the nanopore. Accordingly, as a target polynucleotide, or as a mononucleotide or a probe derived from the target polynucleotide or mononucleotide, transits through or relative to the nanopore, the current across the membrane changes due to base-dependent (or probe dependent) blockage of the nanopore constriction, for example. The signal from that change in current can be measured using any of a variety of methods. Each signal is unique to the species of nucleotide(s) (or probe) in the nanopore, such that the resultant signal can be used to determine a characteristic of the polynucleotide. For example, the identity of one or more species of nucleotide(s) (or probe) that produces a characteristic signal can be determined. The polynucleotide may or may not completely translocate through the nanopore and out into the trans well.
[0080] As used herein, the term “nanopore sequencer” or “nanopore sensor device” refers to any of the devices disclosed herein that can be used for nanopore sequencing. In the examples disclosed herein, during nanopore sequencing, the nanopore is immersed in an electrolyte and a potential difference is applied across the membrane. In an example, the potential difference is an electric potential difference or an electrochemical potential difference. An electrical potential difference can be imposed across the membrane via a voltage source that injects or administers current to at least one of the ions of the electrolyte contained in the cis well or one or more of the trans wells. An electrochemical potential difference can be established by a difference in ionic composition of the cis and trans wells in combination with an electrical potential. The different ionic composition can be, for example, different ions in each well or different concentrations of the same ions in each well. Apparatuses and methods include sequencing polynucleotides and sequencing polypeptides and include providing genomics analysis and proteomics analysis.
[0081] As used herein, a “peptide” refers to two or more amino acids joined together by an amide bond (that is, a “peptide bond”). Peptides comprise up to or include 50 amino acids. Peptides may be linear or cyclic. Peptides may be a, 0, y, 5, or higher, or mixed. Peptides may comprise any mixture of amino acids as defined herein, such as comprising any combination of D, L, a, 0, y, 5, or higher amino acids.
[0082] As used herein, a “protein” refers to an amino acid sequence having 51 or more amino acids.
[0083] As used herein, a “nucleotide” includes a nitrogen containing heterocyclic base, a sugar, and one or more phosphate groups. Nucleotides are monomeric units of a nucleic acid sequence. Examples of nucleotides include, for example, ribonucleotides or deoxyribonucleotides. In ribonucleotides (RNA), the sugar is a ribose, and in deoxyribonucleotides (DNA), the sugar is a deoxyribose, i.e., a sugar lacking a hydroxyl group that is present at the 2' position in ribose. The nitrogen, containing a heterocyclic base, can be a purine base or a pyrimidine base. Purine bases include adenine (A) and guanine (G), and modified derivatives or analogs thereof. Pyrimidine bases include cytosine (C), thymine (T), and uracil (U), and modified derivatives or analogs thereof. The C-l atom of deoxyribose is bonded to N-l of a pyrimidine or N-9 of a purine. The phosphate groups may be in the mono- , di-, or tri-phosphate form. These nucleotides are natural nucleotides, but it is to be further understood that non-natural nucleotides, modified nucleotides or analogs of the aforementioned nucleotides can also be used. [0084] As used herein, “nucleobase” is a heterocyclic base such as adenine, guanine, cytosine, thymine, uracil, inosine, xanthine, hypoxanthine, or a heterocyclic derivative, analog, or tautomer thereof. A nucleobase can be naturally occurring or non-natural. Non-limiting examples of nucleobases are adenine, guanine, thymine, cytosine, uracil, xanthine, hypoxanthine, 8-azapurine, purines substituted at the 8 position with methyl or bromine, 9-oxo-N6-methyladenine, 2-aminoadenine, 7-deazaxanthine, 7-deazaguanine, 7- deaza-adenine, N4-ethanocytosine, 2,6- diaminopurine, N6-ethano-2,6-diaminopurine, 5- methylcytosine, 5-(C3-C6)- alkynylcytosine, 5-fluorouracil, 5-bromouracil, thiouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridine, isocytosine, isoguanine, inosine, 7,8-dimethylalloxazine, 6-dihydrothymine, 5,6-dihydrouracil, 4-methyl-indole, ethenoadenine and the non-naturally occurring nucleobases described in U.S. Pat. Nos. 5,432,272 and 6,150,510 and PCT applications WO 92/002258, WO 93/10820, WO 94/22892, and WO 94/24144, and Fasman ("Practical Handbook of Biochemistry and Molecular Biology", pp. 385-394, 1989, CRC Press, Boca Raton, LO), all herein incorporated by reference in their entireties.
[0085] As used herein, the term “polynucleotide” refers to a molecule that includes a sequence of nucleotides that are bonded to one another. A polynucleotide is one nonlimiting example of a polymer. Examples of polynucleotides include deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and analogues thereof such as locked nucleic acids (LNA) and peptide nucleic acids (PNA). A polynucleotide may be a single stranded sequence of nucleotides, such as RNA or single stranded DNA, a double stranded sequence of nucleotides, such as double stranded DNA, or may include a mixture of a single stranded and double stranded sequences of nucleotides. Double stranded DNA (dsDNA) includes genomic DNA, and PCR and amplification products. Single stranded DNA (ssDNA) can be converted to dsDNA and vice- versa. Polynucleotides may include non-naturally occurring DNA, such as enantiomeric DNA, LNA, or PNA. The precise sequence of nucleotides in a polynucleotide may be known or unknown. The following are examples of polynucleotides: a gene or gene fragment (for example, a probe, primer, expressed sequence tag (EST) or serial analysis of gene expression (SAGE) tag), genomic DNA, genomic DNA fragment, exon, intron, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozyme, cDNA, recombinant polynucleotide, non-natural polynucleotide, branched polynucleotide, plasmid, vector, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probe, primer or amplified copy of any of the foregoing. The term “nucleic acid” may be used interchangeably with “polynucleotide” to refer to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form and, unless otherwise limited, encompasses known analogs of natural nucleotides that hybridize to nucleic acids in manner similar to naturally occurring nucleotides, such as peptide nucleic acids (PNAs) and phosphorothioate DNA. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof. Nucleotides include but are not limited to, ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, TTP, dUTP, 5-methyl-CTP, 5- methyl-dCTP, ITP, diTP, 2-amino-adenosine-TP, 2-amino-deoxyadenosine-TP, 2- thiothymidine triphosphate, pyrrolo-pyrimidine triphosphate, and 2-thiocytidine, as well as the alphathiotriphosphates for all of the above, and 2'-O-methyl-ribonucleotide triphosphates for all the above bases. Modified bases include, but are not limited to, 5-Br-UTP, 5-Br-dUTP, 5- F-UTP, 5-F-dUTP, 5-propynyl dCTP, and 5-propynyl-dUTP.
[0086] For example, a template polynucleotide chain may be any sample that is to be sequenced, and may be composed of DNA, RNA, or analogs thereof (e.g., peptide nucleic acids). The source of the template (or target) polynucleotide chain can be genomic DNA, messenger RNA, or other nucleic acids from native sources. In some cases, the template polynucleotide chain that is derived from such sources can be amplified prior to use. Any of a variety of known amplification techniques can be used including, but not limited to, polymerase chain reaction (PCR), rolling circle amplification (RCA), multiple displacement amplification (MDA), or random primer amplification (RPA). It is to be understood that amplification of the template polynucleotide chain prior to use is optional. As such, the template polynucleotide chain will not be amplified prior to use in some examples. Template/target polynucleotide chains can optionally be derived from non-natural libraries. Non-natural nucleic acids can have native DNA or RNA compositions or can be analogs thereof.
[0087] In some examples, template polynucleotide chains can be obtained as fragments of one or more larger nucleic acids. Fragmentation can be carried out using any of a variety of techniques known in the art including, for example, nebulization, sonication, chemical cleavage, enzymatic cleavage, or physical shearing. Fragmentation may also result from use of a particular amplification technique that produces amplicons by copying only a portion of a larger nucleic acid chain. For example, PCR amplification produces fragments having a size defined by the length of the nucleotide sequence on the original template that is between the locations where flanking primers hybridize during amplification. The length of the template polynucleotide chain may be in terms of the number of nucleotides or in terms of a metric length (e.g., nanometers).
[0088] A population of template/target polynucleotide chains, or amplicons thereof, can have an average strand length that is desired or appropriate for a particular sequencing device. For example, the average strand length can be less than about 100,000 nucleotides, about 50,000 nucleotides, about 10,000 nucleotides, about 5,000 nucleotides, about 1,000 nucleotides, about 500 nucleotides, about 100 nucleotides, or about 50 nucleotides. Alternatively or additionally, the average strand length can be greater than about 10 nucleotides, about 50 nucleotides, about 100 nucleotides, about 500 nucleotides, about 1,000 nucleotides, about 5,000 nucleotides, about 10,000 nucleotides, about 50,000 nucleotides, or about 100,000 nucleotides. Alternatively or additionally, the average strand length can be greater than about 10 kilo nucleotides, about 50 kilo nucleotides, about 100 kilo nucleotides, about 500 kilo nucleotides, about 1,000 kilo nucleotides, about 5,000 kilo nucleotides, about 10,000 kilo nucleotides, about 50,000 kilo nucleotides, or about 100,000 kilo nucleotides. Alternatively or additionally, the average strand length can be greater than about 10 mega nucleotides, about 50 mega nucleotides, about 100 mega nucleotides, about 500 mega nucleotides, about 1,000 mega nucleotides, about 5,000 mega nucleotides, about 10,000 mega nucleotides, about 50,000 mega nucleotides, or about 100,000 mega nucleotides. The average strand length for a population of target polynucleotide chains, or amplicons thereof, can be in a range between a maximum and minimum value set forth above.
[0089] In some cases, a population of template/target polynucleotide chains can be produced under conditions or otherwise configured to have a maximum length for its members. For example, the maximum length for the members can be less than about 100,000 nucleotides, about 50,000 nucleotides, about 10,000 nucleotides, about 5,000 nucleotides, about 1,000 nucleotides, about 500 nucleotides, about 100 nucleotides or about 50 nucleotides. For example, the maximum length for the members can be less than about 100,000 kilo nucleotides, about 50,000 kilo nucleotides, about 10,000 kilo nucleotides, about 5,000 kilo nucleotides, about 1,000 kilo nucleotides, about 500 kilo nucleotides, about 100 kilo nucleotides or about 50 kilo nucleotides. For example, the maximum length for the members can be less than about 100,000 mega nucleotides, about 50,000 mega nucleotides, about 10,000 mega nucleotides, about 5,000 mega nucleotides, about 1,000 mega nucleotides, about 500 mega nucleotides, about 100 mega nucleotides or about 50 mega nucleotides. Alternatively or additionally, a population of template polynucleotide chains, or amplicons thereof, can be produced under conditions or otherwise configured to have a minimum length for its members. For example, the minimum length for the members can be more than about 10 nucleotides, about 50 nucleotides, about 100 nucleotides, about 500 nucleotides, about 1,000 nucleotides, about 5,000 nucleotides, about 10,000 nucleotides, about 50,000 nucleotides, or about 100,000 nucleotides. For example, the minimum length for the members can be more than about 10 kilo nucleotides, about 50 kilo nucleotides, about 100 kilo nucleotides, about 500 kilo nucleotides, about 1,000 kilo nucleotides, about 5,000 kilo nucleotides, about 10,000 kilo nucleotides, about 50,000 kilo nucleotides, or about 100,000 kilo nucleotides. For example, the minimum length for the members can be more than about 10 mega nucleotides, about 50 mega nucleotides, about 100 mega nucleotides, about 500 mega nucleotides, about 1,000 mega nucleotides, about 5,000 mega nucleotides, about 10,000 mega nucleotides, about 50,000 mega nucleotides, or about 100,000 mega nucleotides. The maximum and minimum strand length for template polynucleotide chains in a population can be in a range between a maximum and minimum value set forth above.
[0090] As used herein, the term “signal” is intended to mean an indicator that represents information. Signals include, for example, an electrical signal and an optical signal. The term “electrical signal” refers to an indicator of an electrical quality that represents information. The indicator can be, for example, current, voltage, tunneling, resistance, potential, conductance, inductance, impedance, or a transverse electrical effect (and any time- derivatives or transients of theses). An “electronic current” or “electric current” refers to a flow of electric charge. In an example, an electrical signal may represent an ionic current passing through a nanopore, and the ionic current may flow when an electric potential difference is applied across the nanopore.
[0091] The term “substrate” refers to a rigid, solid support that is insoluble in aqueous liquid and is incapable of passing a liquid absent an aperture, port, or other liquid conduit. In the examples disclosed herein, the substrate may have wells or chambers defined therein. Examples of suitable substrates include wafers, glass and modified or functionalized glass, polymers (including acrylics, polystyrene, and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, polytetrafluoroethylene (PTFE) (such as TEFLON® from Chemours), cyclic olefins/cyclo-olefin polymers (COP) (such as ZEONOR® from Zeon), poly imides, polymethyleneoxide, etc.), nylon, ceramics, silica or silica-based materials, silicon and modified silicon, carbon, metals, inorganic glasses, and optical fiber bundles.
[0092] The terms top, bottom, lower, upper, on, etc., are used herein to describe the device/nanopore sequencer and/or the various components of the device. It is to be understood that these directional terms are not meant to imply a specific orientation but are used to designate relative orientation between components. The use of directional terms should not be interpreted to limit the examples disclosed herein to any specific orientation(s). As used herein, the terms “upper,” “lower,” “vertical,” “horizontal” and the like are meant to indicate relative orientation.
[0093] As used herein, by “translocation,” it is meant that an analyte (e.g., a polynucleotide, such as DNA) moves relative the nanopore opening, but the analyte does not need to move through the nanopore and exit other side of the nanopore opening. For example, the analyte may enter any side of the nanopore, such as the cis side and/or trans side) and may optionally exit the other side of the nanopore opening. For example, the analyte may be translocated multiples times relative to the nanopore in one or more directions, such as cis-to- trans direction, trans-to-cis direction, or both. It is contemplated that any embodiment herein comprising translocation may refer to non-electrophoretic translocation or electrophoretic translocation, unless specifically noted.
[0094] As used herein, the terms "well," "cavity," and "chamber" are used synonymously and refer to a discrete feature defined in the device that can contain a fluid (e.g., liquid, gel, gas). A "cis well" is a chamber that contains or is partially defined by a cis electrode, and is also fluidically connected to a trans well through a respective nanopore. Examples of an array of the present device may comprise one or more cis wells where an individual cis well is a common chamber for a group of trans wells. Each "trans well" is a single chamber that contains or is partially defined by its own trans electrode and is also fluidically connected to a cis well. Each trans well is electrically isolated from the other trans well. In some examples, each trans well is connected to a respective stimulus source and to a respective amplifier (e.g., an on-chip amplifier integrated with a trans electrode) to amplify electrical signals passing through respective nanopores associated with each of the trans wells. In other examples, the trans wells are connected to a single stimulus source which individually addresses the trans wells via multiplexing. Further, it is to be understood that the cross-section of a well taken parallel to a surface of a substrate, at least partially defining the well, can be curved, square, polygonal, hyperbolic, conical, angular, etc.
[0095] One type of nanopore sequencing is strand sequencing. One type of strand sequencing involves the use of a polynucleotide binding protein, such as a motor protein or a helicase to control the movement of the polynucleotide through the nanopore. A polynucleotide binding protein may be used to simultaneously separate the double stranded polynucleotide and control the rate of translocation of the resultant single strand through the nanopore. When a potential is applied across a nanopore, there is a change in the current flow when an analyte, such as a nucleotide, resides transiently in nanopore for a certain period of time. The single polynucleotide strand is passed through the pore and the identities of the nucleotides are derived. Nanopore sequencing instruments that employ strand sequencing includes the MinlON™, GridlON™, and PromethlON™ from Oxford Nanopore Technologies (Oxford, United Kingdom) and the CycloneSEQ™ from BGI Group (Shenzhen, China) and its subsidiaries.
[0096] Another type of strand sequencing involves modifying nucleotides on a strand of polynucleotide to carry a reporter, where the reports include tags or labels to produce a detectable signal. The modified polynucleotide can be translocated through the nanopore (i.e., protein nanopore, solid state nanopore, hybrid nanopore) without a polynucleotide binding protein to control the movement of the polynucleotide. The modified polynucleotide nucleotides on a strand of polynucleotide are described in United States Patent Application Publication US 2009/0035777 Al assigned to Roche Sequencing Solutions Inc. (Pleasanton, California, United States of America).
[0097] Another type of strand sequencing involves modifying nucleotides on a strand of polynucleotide to carry a modification, where the modifications can arrest or slow translocation when encountering the nanopore. The modified polynucleotide can be translocated through the nanopore (i.e., protein nanopore, solid state nanopore, hybrid nanopore) without a polynucleotide binding protein to control the movement of the polynucleotide. In some versions, application of a voltage can move one nucleotide and its attached modification through the nanopore at a time. The modified polynucleotide nucleotides on a strand of polynucleotide are described in PCT International Published Patent Application WO2024/228928 Al by applicant Illumina, Inc. (San Diego, California, United States of America).
[0098] One type of nanopore sequencing involves disposing a polynucleotide within a nanopore. The polynucleotide includes a formed duplex. The duplex may be extended with a polymerase within the nanopore instrument. When a potential is applied across a nanopore, the duplex or extended duplex is held within the nanopore since the size of the constriction of the nanopore inhibits passage of the duplex completely through the nanopore. The electrical signal of the duplex held within the nanopore is used to identify the polynucleotide sequencing. Detecting a polynucleotide duplex is described in PCT International Published Patent Application WO2023/049682A1 Al by applicant Illumina, Inc. (San Diego, California, United States of America).
[0099] Nanopore sequencing as described herein may involve using binding proteins (e.g., motor proteins, helicases) and/or using polymerases. Other types of nanopore sequencing may use exonucleases.
[0100] Analytes have been described herein as polynucleotides. Analytes may further include peptides, polypeptides, proteins, and constructs thereof.
[0101] The aspects and examples set forth herein and recited in the claims can be understood in view of the above definitions.
Nanopore Sequencing System
[0102] FIG. 1A illustrates an example nanopore sequencing system which may be used to implement some embodiments disclosed herein. The example nanopore sequencing system may include a nanopore sequencer 101, which may include a controller 1011 and an array of nanopore unit cells. The controller 1011 may be configured to control the sequencing operations in the array of nanopore unit cells. The example nanopore sequencing system may further include a computer 102 that is operably connected with the nanopore sequencer 101. The example nanopore sequencing system may further include a data storage and computing resource 103, such as a network or cloud, which may be operably connected with the nanopore sequencer 101 and the computer 102.
[0103] In some examples, the control functionalities of controller 1011 can be implemented or performed by a machine, such as a processor configured with specific instructions, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. A processor can be a microprocessor, but in the alternative, the processor can be a controller, microcontroller, or state machine, combinations of the same, or the like. A processor or group of processors for performing the methods described herein may be of various types, including programmable devices (e.g., CPLDs and FPGAs) and non-programmable devices such as gate array ASICs or general-purpose microprocessors.
[0104] A processor can also be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration. For example, systems described herein may be implemented using a discrete memory chip, a portion of memory in a microprocessor, flash, EPROM, or other types of memory. In some examples, a hardware platform for providing a computational environment may be used. The hardware platform may comprise a processor (e.g., CPU) and a memory such as random-access memory (RAM). In some embodiments, graphics processing units (GPUs) can be used. In some embodiments, hardware platforms for performing computational methods as described herein comprise one or more computer systems with one or more processors. In some embodiments, smaller computers are clustered together to yield a supercomputer network. The hardware platform may be specially constructed for the required purposes, or it may be a general-purpose computer (or a group of computers) selectively activated or reconfigured by a computer program and/or data structure stored in the computer. In some embodiments, a group of processors performs some or all of the described functionalities collaboratively (e.g., via a network or cloud computing) and/or in parallel.
[0105] Elements of the methods or processes described herein can be embodied in a software module executed by a processor. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM, or any other form of computer-readable storage medium. An exemplary storage medium can be coupled to the processor such that the processor can read information from, and write information to, the storage medium. In the alternative, the storage medium can be integral to the processor. The processor and the storage medium can reside in an ASIC. A software module can comprise computer-executable instructions which cause a hardware processor to execute the computer-executable instructions.
[0106] FIG. IB illustrates an example of a portion of one of the nanopore unit cells. The nanopore unit cell may include a membrane 118. The membrane 118 can be formed from any suitable natural and/or synthetic material. The membrane 118 may also be formed of a non-permeable or semi-permeable material. In an example, the membrane 118 includes a block copolymer structure or a bilipid layer. The nanopore unit cell may further include a nanopore 120, which may be any of the biological nanopores, solid-state nanopores, and hybrid nanopores. In an example, the nanopore 120 may be a hollow defined by, for example: a polynucleotide structure, a polypeptide structure, or a solid-state structure, e.g., a carbon nanotube, which is disposed in the membrane 118. In a further example, the membrane 118 may be a synthetic membrane (e.g., a solid-state membrane, one example of which is silicon nitride), and the nanopore 120 is in a hollow extending through the membrane 118. In some embodiments, a biological nanopore may be formed of peptides or polynucleotides and deposited in a block copolymer membrane, e.g., a synthetic polymeric membrane. In some embodiments, a solid-state nanopore may be formed as a nanoscale opening in a membrane (e.g., silicon-based, graphene, or polymer membrane).
[0107] The membrane 118 separates the nanopore unit cell into a cis compartment/well and a trans compartment/well. A target polynucleotide can translocate from the cis well, relative to the nanopore 120, to the trans well. A cis electrode 114 is associated with the cis compartment, and a trans electrode 122 is associated with the trans compartment. The electrodes may be used to apply a voltage across the nanopore, thus driving ionic current flows through the nanopore 120 and exerting an electric force on the target polynucleotide. In some examples, the electrodes are faradaic electrodes. In some examples, the electrodes are non-faradaic electrodes. A current detector may be used to measure the ionic current through the nanopore and the detected signal may be transmitted to the sequencer controller 1011. [0108] When a bias is applied across the nanopore 120, a polynucleotide may translocate relative to the nanopore 120. In some embodiments, the polypeptide may translocate from the cis well, relative to the nanopore 120, toward the trans well, or vice versa. When a nucleotide or a sequence combination of nucleotides of the polynucleotide is in or near the nanopore, it may result in a unique ionic current blockade at the nanopore 120 and, therefore, a unique “nanopore resistance” depending on the identity of the nucleotide or the sequence combination of nucleotides. By measuring the ionic current or the “nanopore resistance”, the nucleotide or the sequence combination of nucleotides at or near the nanopore can be identified. In other words, the polynucleotide translocating relative to the nanopore may modulate the electrical properties of the nanopore such that the nucleobase sequence of the polynucleotide can be identified. For example, the current through the nanopore or the electrical resistance at the nanopore may be a function of the identity of the nucleobase of the polynucleotide at or near the nanopore. Furthermore, for the same polynucleotide, the “nanopore resistance” may be different when the polynucleotide is moving through the nanopore in different directions.
[0109] In some embodiments, the target polynucleotide may undergo base pairing during sequencing. In some embodiments, the nucleotides utilized for the base pairing may include a unique tag or label. The tag/label may also result in a unique ionic current blockade at the nanopore 120, and thus can be used for sequencing the target polynucleotide. In some embodiments, a portion of the polynucleotide may translocate through the nanopore from the cis well toward the trans well, but the polynucleotide as a whole does not exit the nanopore into the trans well. In other embodiments, the polynucleotide may translocate through the nanopore from cis well into the trans well.
[0110] In some embodiments, sequencing of a target polynucleotide may involve nanopore sensing of (1) a single-stranded portion of the target polynucleotide; (2) a nucleic acid duplex of a portion of the target poly nucleotide; (3) a label or tag that can be tethered or untethered to the target polynucleotide; (4) chemical modifications thereof, or (5) any combination thereof.
[0111] In some embodiments, multiple nanopore unit cells may be arranged in an array, and each nanopore unit cell may be individually accessed by a logic circuit. In some embodiments, a nanopore array may be present in a nanopore sensor device. [0112] Although embodiments herein describe determining a signal level by determining the ionic current through the nanopore, embodiments also include alone or in combination determining the signal level by measuring other electrical characteristics of the nanopore unit cell. For example, in other embodiments, a signal level is determined by the voltage potential at a specified area or component of the nanopore cell. For example, in other embodiments, a signal level is determined by the conductivity or resistance of the nanopore’s associated membrane. For example, in other embodiments, a signal level is determined by the electrical impedance at a specified area or component of the nanopore cell.
Nanopore Sensor Device
[0113] A nanopore sensor device may have a plurality of nanopore unit cells that forms a sensor array. FIG. 2 depicts an example of a nanopore sensor array 100 that contains a plurality of nanopore unit cells 1000. An example of a nanopore unit cell 1000 is shown in the figure inset. The exemplified nanopore array 100 includes a cis well 12, a cis electrode 14, and a plurality of trans wells 16 separated from the cis well 12 by a polymer/lipid/solid- state/hybrid membrane 18. The membrane 18 contains a plurality of nanopores 20, each associated with a trans well 16 and an individually addressable trans electrode 22. The nanopore(s) 20 may be positioned in, and extend through, the membrane 18 to establish the fluidic connection between the cis well 12 and the trans well(s) 16. The trans wells 16 and the cis well 12 may be filled with an electrolyte solution 24. The trans wells 16 are each associated a trans electrode 22 and are individually addressable. The cis electrode 14 is implemented on the top of the cis well 12. In various embodiments, the width of the cis electrode 14 may be smaller than, larger than or equal to the size of the total or combined widths of the trans wells 16. Thus, a bias voltage is applied between the cis electrode 14 and individual trans electrode 22, which can cause flowing the ions in a direction based on the polarity of the applied bias voltage. For example, if a positive bias voltage is applied (e.g., trans electrode 22 has a positive polarity), the negative charged anions (e.g., A-) in the cis well 12 may move toward the nanopore 20 and the trans well 16, thus generating an ionic current flowing from the cis well 12 to the trans well 16. If a negative bias voltage is applied (e.g., trans electrode 22 has a negative polarity), the negative charged anions (e.g., A-) in the trans well 16 moves toward the nanopore 20 and the cis well 12, thus generating an ionic current flowing from the trans well 16 to the cis well 12. [0114] The cis electrode 14 that is used depends, at least in part, upon the electrolyte species in the electrolyte solution. In some examples, the cis electrode 14 may be an active faradaic electrode that takes part in the chemical reaction with an electrochemically active electrolyte species, and can be oxidized or reduced in the half-cell reaction. Examples of active electrodes include silver (Ag), copper (Cu), zinc (Zn), lead (Pb), intercalation electrodes (e.g. Prussian blue), redox polymers (e.g. PEDOT), etc. In other examples, the cis electrode 14 may be an inactive (or inert, or polarizable) electrode that transfers electrons rather than exchanges ions with the electrolyte solution 24. A polarizable electrode may also induce capacitive charging of ions at the electrode-electrolyte interface without directly exchanging ions with the electrolyte solution. Examples of inactive electrodes include platinum (Pt), carbon (C) (e.g., graphite, diamond, etc.), gold (Au), rhodium (Rh), etc. For example, in the nanopore sensor utilizing an electrolyte solution 24 with an electrically active anion (e.g., chloride, Cl’), the cis electrode 14 may be a silver/silver chloride (Ag/AgCl) electrode.
[0115] The trans electrode 22 that is used depends, at least in part, upon the electrolyte species in the electrolyte solution. The trans electrode 22 may be an active electrode that takes part in the chemical reaction with an electrochemically active electrolyte species, and can be oxidized or reduced in the half-cell reaction. Any of the examples of the active electrodes set forth herein for the cis electrode 14 may be used as the trans electrode 22. In other examples, the trans electrode 22 may be an inactive (or inert) electrode that transfers electrons rather than exchanges ions with the electrolyte solution 24. Any of the examples set forth herein for the cis electrode 14 may be used as the trans electrode 22. In an example, in the nanopore sensor utilizing an electrolyte solution 24 with an electrically active anion (e.g., chloride, Cl’), the trans electrode 22 may be a silver/silver chloride (Ag/AgCl) electrode.
[0116] Many different layouts of the trans wells 16 may be envisaged, including regular, repeating, and non-regular patterns. In an example, the trans wells 16 are disposed in a hexagonal grid for close packing and improved density. Other layouts may include, for example, rectilinear (i.e., rectangular) layouts, triangular layouts, and so forth. As examples, the layout or pattern can be an x-y format of trans wells 16 that are in rows and columns. In some other examples, the layout or pattern can be a repeating arrangement of trans wells 16 and/or interstitial regions 42. In still other examples, the layout or pattern can be a random arrangement of trans wells 16 and/or interstitial regions 42. The pattern may include spots, posts, stripes, swirls, lines, triangles, rectangles, circles, arcs, checks, plaids, diagonals, arrows, squares, and/or cross-hatches.
[0117] The layout may be characterized with respect to the density of the trans wells 16 (i.e., number of trans wells 16 in a defined area of the substrate 26). For example, the trans wells 16 may be present at a density ranging from about 10 wells per mm2 to about 1,000,000 wells per mm2. The density may be tuned to different densities, including, for example, a density of at least about 10 per mm2, about 5,000 per mm2, about 10,000 per mm2, about 0.1 million per mm2, or more. Alternatively or additionally, the density may be tuned to be no more than about 1,000,000 wells per mm2, about 0.1 million per mm2, about 10,000 per mm2, about 5,000 per mm2, or less. It is to be further understood that the density of the trans wells 16 in the support 26 can be between one of the lower values and one of the upper values selected from the ranges above.
[0118] The layout may also or alternatively be characterized in terms of the average pitch, i.e., the spacing from the center of a nanopore 20 to the center of an adjacent nanopore 20 (center-to-center spacing). The pattern can be regular such that the coefficient of variation around the average pitch is small, or the pattern can be non-regular in which case the coefficient of variation can be relatively large. In an example, the average pitch may range from about 100 nm to about 500 pm. The average pitch can be, for example, at least about 100 nm, about 5 pm, about 10 pm, about 100 pm, or more. Alternatively or additionally, the average pitch can be, for example, at most about 500 pm, about 100 pm, about 50 pm, about 10 pm, about 5 pm, or less. The average pitch for an example array including a particular pattern of nanopores 20 can be between one of the lower values and one of the upper values selected from the ranges above. In an example, the array has an average pitch (center-to-center spacing) of about 10 pm.
[0119] The trans wells 16 may be micro wells (having at least one dimension on the micron scale, e.g., about 1 pm up to, but not including, 1000 pm), such as from about 1 pm to about 750 pm, such as from about 5 pm to about 500 pm, such as from about 10 pm to about 250 pm, such as from about 15 pm to about 100 pm. Each trans well 16 may be characterized by its aspect ratio (e.g., depth or height divided by width or diameter).
[0120] In certain embodiments, the trans wells 16 have an aspect ratio from about 1:10 to about 10:1, from about 1:2 to about 5: 1, or from about 2:3 to about 2: 1 [0121] The depth/height and width/diameter may be selected in order to obtain a desirable aspect ratio. The depth/height of each trans well 16 can be at least about 0.1 pm, about 1 pm, about 10 pm, about 100 pm, or more. Alternatively or additionally, the depth can be at most about 1,000 pm, about 100 pm, about 10 pm, about 1 pm, about 0.1 pm, or less. The width/diameter of each trans well 16 can be at least about 0.1 pm, about 0.5 pm, about 1 pm, about 10 pm, about 100 pm, or more. Alternatively or additionally, the width/diameter can be at most about 1,000 pm, about 100 pm, about 10 pm, about 1 pm, about 0.5 pm, about 0.1 pm, or less.
[0122] Each trans well 16 has an opening (e.g., that faces the cis well 12) that is large enough to accommodate at least a portion of the membrane 18 and the nanopore 20 that is associated therewith. For example, an end of the nanopore 20 may extend through the membrane 18 and into the opening of the trans well 16.
[0123] The cis well 12 and the trans wells 16 may be fabricated using a variety of techniques, including, for example, photolithography, nanoimprint lithography, stamping techniques, embossing techniques, molding techniques, microetching techniques, etc.
[0124] The membrane 18 may be any of the non-permeable or semi-permeable materials described herein. The membrane 18 is positioned between the cis well 12 and the trans wells 16, and thus provides a barrier between the wells 12 and 16. The membrane may be positioned on the interstitial region 42 of the substrate 26.
[0125] The nanopore(s) 20 may be any of the biological nanopores, solid state nanopores, and hybrid nanopores described herein. As mentioned herein, each nanopore 20 fluidically connects a respective one of the trans wells 16 to the cis well 12. As such, the ratio of nanopores 20 to trans wells 16 is 1: 1.
[0126] The nanopore 20 has two open ends and a hollow core or hole that connects the two open ends. The walls of the hollow core or hole are an inner surface of the nanopore 20. When inserted into the membrane 18, one of the open ends of the nanopore 20 faces the cis well 12 and the other of the open ends of the nanopore 20 faces the trans well 16. The hollow core of the nanopore 20 enables the fluidic connection between the wells 12, 16. The diameter of the hollow core may range from about 1 nm up to 1 pm, and may vary along the length of the nanopore 20. In some examples, the open end that faces the cis well 12 may be larger than the open end that faces the trans well 16. In other examples, the open end that faces the cis well 12 may be smaller than the open end that faces the trans well 16.
[0127] The nanopore(s) 20 may be inserted into the membrane 18, or the membrane 18 may be formed around the nanopore(s) 20. In an example, the nanopore 18 in its monomeric form or oligomeric form (e.g., an octamer, nonamer, etc.) may insert into a formed bilayer (one example of the membrane 18). For example, the nanopore may insert into a bilayer through electroporation, pipette pump cycle, and/or detergent assisted pore insertion. For example, an oligomeric nanopore 20 may assemble into a nanopore and insert into the bilayer. In another example, the nanopore 20 may be added to a well of a bilayer at a desirable concentration where it will insert into the bilayer. In yet a further example, the nanopore 20 may be inserted into to a solid support (e.g., silicon, silicon oxide, quartz, indium tin oxide, gold, polymer, etc.). An anchoring molecule, which may be part of the nanopore 20 or may be attached to the nanopore 20, may attach the nanopore 20 to the solid support. The attachment via the anchoring molecule may be such that a single nanopore 20 is immobilized (e.g., between two chambers/wells). A bilayer may then be formed around the nanopore 20. The nanopore sensor device 100 includes an electrolyte solution 24 in the cis well 12 and the trans wells 16.
[0128] The electrolyte may be any electrolyte that is capable of dissociating into cations and anions. For example, the salt may include any suitable combination of cations (such as, but not limited to, H+, Li+, Na+, K+, NH4+, Ag+, Ca2+’ Ba2+, and/or Mg2+) with any suitable combination of anions (such as, but not limited to, OH', Cl', Br', I', NCb', ClOF, F', SO42', and/or CO?2'.). In one example, the electrolyte can be for an Ag/AgCl redox system. In another example, the electrolyte may also be one or more salts of a a redox mediator system, such as ferrocyanide/ferricyanide redox couple in an electrolyte buffer in which ferrocyanide ions (e.g., Fe(CN)e4') are oxidized to ferricyanide ions (e.g., Fe(CN)e3') and ferricyanide ions (Fe(CN)e3') are reduced to ferrocyanide ions (Fe(CN)e4'). In this case, the mediator system may be combined with a secondary electrolyte species (e.g., KC1). It is believed that O-company uses ferrocyanide/ferricyanide.
[0129] The nanopore sensor device 100 also includes electronics to individually and/or collectively address each of the trans electrodes 22. As mentioned herein, each of the trans electrodes 22 is associated with a respective trans well 16 and a respective nanopore 20. The electronics include at least a stimulus source and a controller. As shown in the embodiment of FIG. 2, a function generator 19 is applied to a common cis electrode 14 for a plurality of trans wells 16. As shown in the embodiment of FIG. 2, each of the trans electrodes comprises electronics 17 to individually address each of the trans electrodes 22 by applying a waveform and by individually measuring a signal from the trans electrode. A controller 23 is coupled to the function generator 19 and the electronics 17 to control current flow through an individual nanopore 20 by addressing an individual trans electrodes 22. The controller is coupled to the stimulus source, and the controller is configured to individually/selectively address one of the plurality of trans electrodes 22 (using the stimulus source) to cause an ionic current to flow through the nanopore 20 connected to the addressed trans electrode 22. The electronics may also include amplifier(s) to amplify electrical signals passing through respective nanopores 20 associated with trans electrodes 22 that are addressed.
[0130] In some embodiments, the stimulus source applies a voltage bias between the cis well 12 and at least one of the plurality of trans wells 16 (using the electrodes 14, 22), and thus across the nanopore 20 and the membrane 18. The voltage bias that is applied may be a positive polarity to the trans electrode 22 to attract negative charge compounds (such as negatively charge nucleotides, negatively charged labels/tags) in the cis well 12 towards the nanopore 20 and/or a negative polarity to the trans electrode 22 to repel negatively charged compounds (such as negatively charge nucleotides, negatively charged labels/tags) in the cis well 12 away from the nanopore 20. In some embodiments, the voltage bias ranges from about -10 V to about 10 V, from about -5 V to about 5 V, from about -2 V to about 2 V, or from about -1 V to about 1 V between the cis electrode 14 and the trans electrodes 22 during a sensing or sequencing cycle. Any voltage bias within the given range may be applied during a sensing or sequencing cycle. For example, when measuring nucleobase identities (sequencing phase), the voltage bias may range from about -200 mV to about 200 mV; during nonmeasurement, such as ejection, capturing or recharging phases (which will be explained in more details below), the voltage bias may range from about 0 mV to about 500 mV, or from about -1000 mV to about 1000 mV in various phases. In certain examples, the nanopore sensor device 100 operates in a bipolar mode (e.g., alternating current), providing a negative bias and a positive bias to the trans electrode 22. In certain examples, the nanopore sensor device 100 operates in a unipolar mode (e.g., direct current), providing a negative bias to the trans electrode 22. In some instances, the voltage can be reduced, or the polarity reversed, to facilitate appropriate function.
[0131] Certain embodiments described herein are related to providing a net-zero or near- zero current scheme for a nanopore array during polynucleotide sequencing. A voltage can be applied between the cis electrode and the individual trans electrodes, and thus, an ionic current can pass through each nanopore in the array.
[0132] In some embodiments, for manufacturing efficiency and cost saving purposes, it is desirable to have an external (i.e., off the chip) cis electrode as part of a microfluidics setup while having sensing electrodes/trans electrodes addressing each nanopore embedded in the chip. The cis electrode can be places several centimeters from the chip surface.
[0133] In some cases, the actual voltage difference across a nanopore is not the same as the voltage applied between the cis electrode and the nanopore’s corresponding trans electrode, because the electrolyte connection between the cis electrode and the nanopore has a non- zero electrical resistance. The electrolyte connection between the cis electrode and the nanopores has a resistance Rs (i.e., series resistance or solution resistance) that may depend on factors such as salt concentration and the length and the diameter of the fluidics connection between the electrode and the chip surface. In some cases, when a voltage is applied between the cis and trans electrodes, the actual voltage difference across a nanopore would depend on Rs and further on the “nanopore resistances” that relate to how easily ions can go through the nanopore unit cells given the states of the membranes, pore proteins and polynucleotides in or near the nanopores.
[0134] FIG. 3 A illustrates an equivalent circuit diagram of the nanopore device 100 as depicted in FIG. 2. Each “nanopore resistance” Rpi 124 represents the resistance of a single nanopore unit cell, where i=l, 2, 3, ... , N, and depends on the parameters of the unit cell and the states of the associated membrane, nanopore and polynucleotide in or near the nanopore. In a sensor array, the collection of all nanopore unit cells can be viewed as an array of parallel resistors with a total resistance Rptot, which can be calculated according to 1 /Rptot = 1/Rpi + 1/Rp2 + . . . + 1/RpN. Thus the total resistance Rptot in a large array can be orders of magnitude smaller than that of single or few unit cell. For example, an array of 100,000 nanopore unit cells where each individual nanopore unit cell features a resistance of IGOhm would have a total resistance of only lOkOhm. For large enough arrays of nanopore unit cells, the total resistance of all nanopore unit cells can therefore become comparable to the resistance of the electrolyte connection leading to the cis electrode. When a voltage Vbias 126 is applied to the cis electrodel4, the voltage drop across the buffer resistance Rs 130 can be calculated by Vs = Is * Rs, where Is is the current flowing through Rs (and equals to the sum of currents through each nanopore unit cells). As a result, the voltage at the cis end of the nanopores Vois is therefore Vois = Vbias - Vs. In some embodiments, it may be preferred that Vois be controlled to within about within about 0.1 mV, within about 1 mV, or within about 5 mVof a desired value. However, since Is is also the sum of the currents going through each individual nanopore unit cells, any change in the total current Is is reflected in a shift in Vs and therefore a change in the Vois applied to the cis end of the nanopores.
[0135] As illustrated by FIG. 3A, while all the nanopore unit cells share the same Vois, the voltage applied to each individual trans electrode, Vtrans.i, where i=l, 2, 3, ... , N, are individually controlled (by an associated active circuitry in the ASIC layer). Therefore the voltage difference across each individual nanopore unit cell, Vois-Vtrans,i, can be individually controlled. This allows for independent actuation of the nanopore unit cells and the motion (e.g., direction and/or speed) of polynucleotides in nanopores. Therefore, the nanopore sequencing device shown in FIG. 2 can achieve asynchronous sequencing, i.e., sequencing at different unit cells may occur at different times.
[0136] Changes of the total current in the system can occur in multiple ways. For example, it may be necessary to turn off a nanopore sensor during a sequencing run if the membrane supporting the nanopore breaks, or if multiple pores are present in a membrane for an individual trans well. When the total number of active channels is reduced in this way the total resistance of the system increases and thus causing the total current to decrease. In some instances, a sensor’s bias voltage may need to be changed independently for a particular stage of the sequencing process. For example, individual sensors can be set to a number of different voltages to enable ejection of a used (i.e., completed sequencing) or stalled polynucleotide from a nanopore, replenishing of electrochemical components inside a cis/trans well, or capturing of a fresh polynucleotide in the nanopore. Depending on the bias state of a trans electrode the current going through the respective pore can become larger, smaller, and even opposite in sign to the typical current observed in the sequencing mode. In some instances, electrolyte may be depleted due to different ionic species being transported across the nanopore at different rates, which can cause a shift in electrolyte composition in the sensor’s trans well. This could affect the pore conductivity due to asymmetric salt conditions as well as the junction potential at the sensing electrode. The current may also change due to intrinsic pore noise that is in part induced by fast conformational changes of the pore protein. Different polynucleotide sequences also cause specific changes in the pore resistance (and thus observed pore current) as the polynucleotide translocate relative to the nanopore. Furthermore, different number of nanopores may be present in the array between setups. Loading the individual channels/wells with nanopores is related to the fluid concentration of nanopores that is subject to process variations, which leads to pore insertion in fewer than all of the desired individual channels/wells. While a pore resistance during a run may not be significantly affected by a neighboring channel/well without an inserted pore, the variability of pore insertion may be accounted for in order to control Vois.
[0137] Shifting Vois bias is undesirably more pronounced the larger the sensor array becomes since the nanopore array’s resistance gets smaller with respect to the fluidic resistance Rs. FIG. 3B is showing the effect on Vois in response to a 10% change in Rptot for different ratios of Rptot/Rs. The voltage drop, Vs, across Rs depends linearly on the total current, according to Vs = Is*Rs. The current Is may be minimized by balancing the current between neighboring channels in the nanopore array and by mitigating the adverse voltage drop effect across the fluidic line.
[0138] To address these limitations, certain embodiments provide achieving a net- zero or near-zero electrical current flow through the nanopore array. This may be accomplished by controlling the state of nanopore unit cells to achieve zero net current flow. For example, as illustrated in FIG. 4, the currents in different unit cells differ in magnitudes and directions, such that the sum of currents is approximately zero. As a result, when the total net current flowing through the nanopores is zero or close to zero, the voltage drop Vs is zero or close to zero and thus the voltage difference applied to the nanopores can be known to a greater precision (i.e., equal or close to Vbias-Vtrans,i). This allows more precise control of the polynucleotide motion relative to the nanopore and more accurate determination of Ri by measuring li, for example. [0139] In some embodiments, a unit cell with an open well where no membrane was formed, a unit cell with a burst or non-intact membrane, a unit cell with an intact membrane where no nanopore was formed, a unit cell with a membrane having an open nanopore without an analyte, and/or a unit cell with a membrane having multiple nanopores is used to balance currents in the array of nanopore unit cells to achieve net-zero or near-zero current. For example, nanopore unit cells in these states may be applied with a reverse current (e.g., used for recharging) opposite to a forward current (e.g., used for sequencing) applied to a nanopore unit cell with a membrane having a nanopore in which a polynucleotide is inserted.
[0140] In certain embodiments a controller, such as controller 1011 of FIG. 1A, of the instrument calculates the amount of current consumed over time to determine which wells/electrodes to apply a forward or reverse current. In some embodiments, the controller may be a FPGA.
[0141] In some embodiments, the nanopore device correlates the measured electrical characteristics with the sequencing process. In these embodiments, the current flow direction can correspond to the stages of the sequencing process. For example, as shown in FIG. 5A, when a positive bias is applied at the trans electrode relative to the cis electrode, anions can flow from the cis well to the trans well, which creates a “forward current.” A polynucleotide, being negatively charged, is also attracted to the positively biased trans electrode and moves from the cis well towards the trans well. This causes the polynucleotide to translocate relative to the nanopore towards the trans well. In another example, when the bias is reversed and a negative bias is applied at the trans electrode relative to the cis electrode, anions can flow from the trans well into the cis well. Similarly, the negatively charged polynucleotide is repelled by the negatively biased trans electrode and results in translocation of the polynucleotide relative to the nanopore away from the trans wells. This direction can generally be referred to as a “reverse current.”
[0142] In another example, during the recharging stage, when the nanopore may be an open nanopore without a captured polynucleotide, the ionic concentrations in the cis and the trans wells may be rebalanced by negatively biasing the trans electrode to provide a reverse current moving anions from the trans well into the cis well. In some cases, during the recharging stage the nanopore may have an analyte (e.g., polynucleotide) in it. In another example, during a capturing stage of the sequencing process of a polynucleotide introduced to a cis well, a positive bias is applied at the trans electrode to provide a forward current and to capture the polynucleotide by the nanopore of the trans well.
[0143] In some nanopore unit cells, no polynucleotide is captured by a nanopore which is inserted in a membrane; this situation is termed an “open pore” state and is associated with either a forward or a reverse current, depending on the polarity of the difference between Vtrans and Vois. In some nanopore unit cells, no nanopore is inserted in the membrane and thus no current can flow through the unit cell. If the magnitude of (Vtrans and Vois) increases beyond a threshold value, the membrane may break (or rupture or burst). In nanopore unit cells where membrane is broken or not painted, and thus also without pore protein, current flows in either the forward or the reverse direction, depending on the polarity of the difference between Vtrans and Vois. FIG. 5A is a schematic illustration of certain embodiments of sequencing using double-stranded and/or single stranded portions of DNA. Embodiments of present apparatus and methods include (1) a single-stranded portion of the target polynucleotide; (2) a nucleic acid duplex of a portion of the target polynucleotide; (3) a label or tag that can be tethered or untethered to the target polynucleotide; (4) chemical modifications thereof, or (5) any combination thereof. FIG. 5 A illustrates certain embodiments wherein ejection occurs from the cis well with a reverse current. In other embodiments, ejection occurs from the trans well with a forward current. FIG. 5A illustrates certain embodiments wherein capture occurs from the cis well with a forward current. In other embodiments, capture occurs from the trans well with a reverse current. FIG. 5A illustrates the flow of anions during certain embodiments of sequencing, ejection, recharging, and capture in which the anions comprise chlorine (Cl’) anions. In other embodiments, the anions may be any suitable anions.
[0144] In some aspects, certain embodiments provide a nanopore device with a net- zero or near net-zero current scheme that can minimize the total current in the nanopore array. In some embodiments, the net-zero or near net-zero total current can be achieved by balancing the amount of forward current and reverse current from all the nanopore unit cells in the array. For example, the nanopore device determines the electrical characteristics of each nanopore unit cell to infer its state. For example, the forward current flows when the state is sequencing or capturing a polynucleotide, and the reverse current flows when the state is recharging and/or ejection. For example, the flux of anions passing in a reverse flowing direction per unit of time during the recharging state and/or ejection station is balanced with the flux of anions passing in the forward direction per unit of time during the sequencing state and/or capturing state. In certain embodiments, the nanopore device can balance the currents in the nanopore unit cells to achieve the net-zero or near net-zero total current to provide a reduced voltage drop across the cis well. In certain embodiments, the nanopore device can balance the currents in the nanopore unit cells to achieve the net-zero or near net-zero total current or charge to replenish the electrolytes within the nanopore cells, such as replenishing the ions in the trans well. In certain embodiments, the nanopore device can balance the currents in the nanopore unit cells to achieve the net- zero or near net-zero total current or charge to replenish the redox mediators within the nanopore cells or restore the balance of redox mediators (e.g., ferrocyanide and ferricyanide) in the trans well. For example, if the nanopore device includes 10 nanopore unit cells and all of the 10 nanopore unit cells are in the sequencing state, the system can change the state of two nanopore unit cells into recharging. In this example, if the sum of currents in the two recharging nanopore unit cells can compensate the sum of currents in the other eight nanopore unit cells, the total current in these ten nanopore unit cells is zero or near zero. These numbers are merely used for illustration, and the actual numbers and parameters used to change the states can be determined based on specific applications.
[0145] In some embodiments, changing the state for each nanopore unit cell can be performed by implementing a circuitry configured to control the state. The state, for example, can include sequencing, ejecting, recharging, and capturing. The circuitry can be utilized to perform the controlling scheme of the nanopore device. For example, during the sequencing and/or capturing states, the circuitry may generate positive bias voltage meaning that the voltage that enables the potential at trans wells is higher than the cis well. In another example, during the ejecting and/or recharging states, the circuitry may generate a negative bias to enable the cis well to have a higher potential than the trans well. The magnitude of the potential difference in each state can also be varied, such that the recharging state can have a higher magnitude than the sequencing state.
[0146] Waveforms during sequencing can be DC, stepped, pulsed, AC, or combinations thereof. With reference to the various phases shown in FIG. 5A, FIG. 5B shows an example waveform that is positive stepped during the sequencing phase, and negative DC during the ejection period. In another aspect, certain embodiments provide the net-zero or near net-zero total current scheme by generating a plurality of waveforms, where each waveform can provide both positive bias voltage and negative bias voltage during different time periods. For example, the waveforms may be sinusoidal. In some embodiments, two or more waveforms can be utilized and applied to different trans electrodes at the same time to achieve the net-zero total currents. In these embodiments, these waveforms may be identical other than that they have different phase shifts. For example, if there are two waveforms with 180 degree phase difference, the first waveform can be applied to a first subset of nanopores and the second waveform can be applied to a second subset of nanopores. Thus, the first subset of nanopores can have positive bias voltage and provides forward current, while the second subset of nanopores can have reverse bias voltage and provides reverse current. These forward currents and reverse currents can compensate each other, and the net current in the array can be zero or near zero.
[0147] Certain embodiments can implement at least one processor and memory to perform one or more aspects and examples, as disclosed herein. Embodiments described herein are not limited by the type or quantity of these processors and memory.
Example 1
[0148] FIG. 6A illustrates one example scheme of balancing currents to achieve net-zero of near zero total current in the nanopore array. In the first step, the system determined the state of each nanopore cell of the nanopore array, where the state may be one of:
• Non-intact/burst barrier/membrane
• Intact barrier/membrane
• Intact barrier/membrane with an inserted pore (open pore)
• Intact barrier/membrane with an inserted pore and a captured DNA strand/template
[0149] In the second step, the system then individually applied waveforms to two sub-sets of the nanopore cells so that the net current was approximately zero, where the two subsets were:
• Subset (1): Sequencing of captured DNA/strand template. Two example sequencing processes used in conjunction with this scheme were described in U.S. Patent Application Nos. 17/933,833 and 18/311,876.
• Subset (2): Recharging of open pore or blocked pore [0150] The system may repeat the first step and the second step at the end of the second step, or after a portion of the waveform’s period.
Example 2
[0151] FIG. 6B illustrates one example scheme of balancing currents to achieve net-zero of near zero total current in the nanopore array. In the first step, the system determined the state of each nanopore cell of the nanopore array, where the state may be one of:
• Non-intact/burst barrier/membrane
• Intact barrier/membrane
• Intact barrier/membrane with an inserted pore (open pore)
• Intact barrier/membrane with an inserted pore and a captured DNA strand/template
[0152] In the second step, the system then individually applied waveforms with positive bias or negative bias to sub-sets of the nanopore cells (via the trans electrodes) so that the net current was approximately zero, where the subsets were:
• Subset (1): Sequencing of captured DNA/strand template. Two example sequencing processes used in conjunction with this scheme were described in U.S. Patent Application Nos. 17/933,833 and 18/311,876. This subset will be applied with positive potential on their trans electrodes.
• Subset (2): Capture of DNA strand/template. This subset will be applied with positive potential on their trans electrodes.
• Subset (3): Combinations of (1) and (2). This subset will be applied with positive potential on their trans electrodes.
• Subset (4): Recharging of open pore. This subset will be applied with negative potential on their trans electrodes.
• Subset (5): Ejection of the DNA strand/template. This subset will be applied with negative potential on their trans electrodes.
• Subset (6): Combinations of (4) and (5). This subset will be applied with negative potential on their trans electrodes.
[0153] The system may repeat the first step and the second step at the end of the second step, or after a portion of the waveform’s period. Example 3
[0154] FIG. 7A, FIG. 7B and FIG. 7C illustrate some example schemes of balancing currents to achieve net-zero of near zero total current in the nanopore array. In these schemes, the system individually applied AC (e.g., sinusoidal) waveforms to two or more subsets of the nanopore cells so that the net current is approximately zero.
[0155] An example sequencing processes used in conjunction with these schemes were described in U.S. Patent Application No. 17/933833. FIG. 7A illustrates that two waveforms 180 degrees out of phase were applied to two subsets of the nanopore cells. FIG. 7B illustrates that three waveforms 120 degrees out of phase were applied to three subsets of the nanopore cells. FIG. 7C illustrates that four waveforms 90 degrees out of phase were applied to four subsets of the nanopore cells.
Workflows for Balancing Currents
[0156] Embodiments can include also unhealthy unit cells (multiple pores inserted into the membrane of a unit cell) and open wells (ruptured membrane in a unit cell) as control mechanism or even rupturing on purpose leading to more open wells to have more current flow and thus balancing capacity available.
[0157] Either open pore currents or even an external probe (e.g., between ground and the electrodes) may be used as a measure of the voltage bias variability. Calculating the currents on a per channel basis is another embodiment to knowing the sum of current passing in each direction. For example, net current measurements can be done by monitoring the current on the cis electrode, or by measuring open pore currents and inferring bias drifts from that (e.g., and then concluding that net current is zero when the bias drop across the buffer is zero and therefore the open pore current is within specified bounds).
[0158] From either calculating or measuring, the needed sum of negative currents would be inferred at each stage of the sequencing process, as illustrated by FIG. 8. For example, the unit cells going into the capturing state would be limited based on the imbalanced current allowed and available current flow capacity (open wells, creating open wells from unhealthy open pores and open pores which are not capturing). If zero imbalanced currents is allowed (which means at all times the net current needs to be zero which limits the active channels depending on the available current flow capacity), that limit would not be there as a little current flow in one direction would be allowed for some time, maybe up to one full sequencing run on a number of cells, and then current balancing can be achieved additionally by coordinating the states with other cells. Through a prior adjustment (e.g., considering the tradeoff between perfect current balancing versus sequencing throughput), a combination of all current adjustment mechanisms and their ratio to each other would be determined (using only current balancing capacity or allow a certain amount of net current resulting in a slight shift in voltage leading to potentially base call errors depending on the robustness of the base caller).
[0159] Additionally or alternatively, zero net current may not be strictly required at all times. For example, on the short time scale (e.g., within a sequencing state time scale) only strictly zero net current is allowed, while on the longer time scale (e.g., including switches between states, such as from the sequencing state to the recharging state or capturing state) the net current is allowed to deviate from zero by a little. Unit cells that can be utilized to balance the currents include:
• Open wells/unhealthy open pores.
• Zapped unhealthy open pores to increase balancing capacity.
• Potentially healthy open pores (which should capture but can be redirected to current balance).
• Unusable cells where the membrane is inserted with multiple pores
• Membranes that a pore would not insert into and have been intentionally zapped
• Depleted cells that a pore remains so that another pore could not be inserted, and therefore the membrane was zapped
Allowing a little unbalanced current flow resulting in a slight total bias shift (+-2mV, e.g.), which enables more unit cells to go into capturing. An example of assembling unit cells according to their waveforms to achieve net zero or near zero current is illustrated in FIG. 9. Additional ways to tune the currents in the system include:
• Using the recharge state to balance on top of the other mechanisms (driving current through the wells/pores).
• Prolongating the eject state to balance - delaying the unit cell in this sate to have more current flowing through.
• Delaying unit cells going into capture to create more time to balance if needed. Example Workflow
1) Determine current balancing capacity (available unhealthy pores, open pores after insertion, and/or open wells versus healthy open pore channels),
2) Zap intact membranes/ open pores/unhealthy pores to have more open wells or use open pores for “smooth, fine” balancing in combination with “coarse” open well currents - determined by the priority.
3) Start capturing only with a safe number of channels depending on priority and the current balancing capacity.
4) Add more channels in with current balancing them only close to real time within the waveform by “phase shifting” similar to above graphs (timescale seconds, embodiment 3 graph).
5) Balancing the array charge on a minutes to hours basis within the workflow with channels having reached the recharging state and only then incorporate more channels to go through the sequencing work flow. Number of channels allowed to start at the same time is determined by the minimum current imbalance allowed and the number of channels available to balance.
6) Balancing the array in real time with little to no current imbalance by switching available balancing channels (open wells/pores) into eject state (fixed negative voltage) or recharging state (smaller fixed voltage than eject state) to balance the channels in other states, due to DAC limitations any device will probably have to use the voltages programmed into existing DACs with assigned functions other than charge balancing (compromise in efficiency).
7) Combination of l)-6).
8) If not enough, delay capturing.
9) If not enough, delay sequencing.
10) If first channel has recharged and is ready to capture again but not enough charge is available, delay these “secondary sequencing” channels.
[0160] In some embodiments, it requires recharging on a per unit cell basis so that the open wells would not deplete for a future run, which could be done with the recharging step. In these embodiments, a charge counter for all unit cells and an array net charge counter are needed, while a current measurement is not needed (but still would be helpful for precise data or faster reaction time as opposed to a software estimate).
[0161] In some embodiments, the workflows need to be actively summing all unit cells’ currents and adjust the counter currents within a time frame given by the allowed net current for safe sequencing.
[0162] In some embodiments, only the initial state of the nanopore array needs to be considered to determine how many unit cells can start to capture polynucleotides for sequencing, since the first, capturing state is the one with the most net current due to the high voltage the capturing applies and the low resistance without template. So, if the ratio of open wells/open pores is such that it can balance the capturing channels, then all other states afterward are within that scenario and boundaries because capturing is the most current intense state.
Additional Notes
[0163] It should be appreciated that all combinations of the foregoing concepts and additional concepts discussed in greater detail below (provided such concepts are not mutually inconsistent) are contemplated as being part of the inventive subject matter disclosed herein. In particular, all combinations of claimed subject matter appearing at the end of this disclosure are contemplated as being part of the inventive subject matter disclosed herein. It should also be appreciated that terminology explicitly employed herein that also may appear in any disclosure incorporated by reference should be accorded a meaning most consistent with the particular concepts disclosed herein.
[0164] Reference throughout the specification to “one example”, “another example”, “an example”, and so forth, means that a particular element (e.g., feature, structure, and/or characteristic) described in connection with the example is included in at least one example described herein, and may or may not be present in other examples. In addition, it is to be understood that the described elements for any example may be combined in any suitable manner in the various examples unless the context clearly dictates otherwise.
[0165] It is to be understood that the ranges provided herein include the stated range and any value or sub-range within the stated range, as if such value or sub-range were explicitly recited. For example, a range from about 2 nm to about 20 nm should be interpreted to include not only the explicitly recited limits of from about 2 nm to about 20 nm, but also to include individual values, such as about 3.5 nm, about 8 nm, about 18.2 nm, etc., and sub-ranges, such as from about 5 nm to about 10 nm, etc. Furthermore, when “about” and/or “substantially” are/is utilized to describe a value, this is meant to encompass minor variations (up to +/- 10%) from the stated value.
[0166] While several examples have been described in detail, it is to be understood that the disclosed examples may be modified. Therefore, the foregoing description is to be considered non-limiting.
[0167] While certain examples have been described, these examples have been presented by way of example only, and are not intended to limit the scope of the disclosure. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the systems and methods described herein may be made without departing from the spirit of the disclosure. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the disclosure.
[0168] Features, materials, characteristics, or groups described in conjunction with a particular aspect, or example are to be understood to be applicable to any other aspect or example described in this section or elsewhere in this specification unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing examples. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
[0169] Furthermore, certain features that are described in this disclosure in the context of separate implementations can also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation can also be implemented in multiple implementations separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations, one or more features from a claimed combination can, in some cases, be excised from the combination, and the combination may be claimed as a sub-combination or variation of a sub-combination.
[0170] Moreover, while operations may be depicted in the drawings or described in the specification in a particular order, such operations need not be performed in the particular order shown or in sequential order, or that all operations be performed, to achieve desirable results. Other operations that are not depicted or described can be incorporated in the example methods and processes. For example, one or more additional operations can be performed before, after, simultaneously, or between any of the described operations. Further, the operations may be rearranged or reordered in other implementations. Those skilled in the art will appreciate that in some examples, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the example, certain of the steps described above may be removed or others may be added. Furthermore, the features and attributes of the specific examples disclosed above may be combined in different ways to form additional examples, all of which fall within the scope of the present disclosure. Also, the separation of various system components in the implementations described above should not be understood as requiring such separation in all implementations, and it should be understood that the described components and systems can generally be integrated together in a single product or packaged into multiple products. For example, any of the components for an energy storage system described herein can be provided separately, or integrated together (e.g., packaged together, or attached together) to form an energy storage system.
[0171] For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. Not necessarily all such advantages may be achieved in accordance with any particular example. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
[0172] Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain examples include, while other examples do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more examples or that one or more examples necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular example.
[0173] Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain examples require the presence of at least one of X, at least one of Y, and at least one of Z.
[0174] Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result.
[0175] The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred examples in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.

Claims

WHAT IS CLAIMED IS:
1. A method of generating a net-zero or near- zero current scheme in an array of nanopore unit cells, the method comprising: determining a state of a nanopore unit cell of the array of nanopore unit cells; and applying a waveform to the nanopore unit cell based at least on the determined state of the nanopore unit cell.
2. The method as defined in claim 1, wherein the state comprises: a unit cell with an open well where no membrane was formed, a unit cell with a burst or non-intact membrane, a unit cell with an intact membrane where no nanopore was formed, a unit cell with a membrane having an open nanopore without an analyte, a unit cell with a membrane having a nanopore in which an analyte is inserted, or a unit cell with a membrane having multiple nanopores.
3. The method as defined in claim 1, wherein a unit cell with an open well where no membrane was formed, a unit cell with a burst or non-intact membrane, a unit cell with an intact membrane where no nanopore was formed, a unit cell with a membrane having an open nanopore without an analyte, and/or a unit cell with a membrane having multiple nanopores is used to balance currents in the array of nanopore unit cells to achieve net-zero or near-zero current.
4. The method as defined in claim 1, comprising: dividing the array of nanopore unit cells into sub-groups based at least on the determined state of each individual nanopore unit cell; and applying a waveform to each sub-group.
5. The method as defined in claim 4, wherein the sub-groups comprise sequencing, ejecting, recharging, and capturing.
6. The method as defined in claim 5, wherein the sequencing and capturing subgroups are associated with forward currents, and wherein the ejecting and recharging subgroups are associated with reverse currents.
7. The method as defined in claim 1, comprising determining the state of an individual nanopore unit cell based on the magnitude and/or direction of the current flowing through the individual nanopore unit cell.
8. The method as defined in claim 1, further comprising, in response to determining that total current of the array is not zero or is above a predetermined threshold, changing the state of at least one nanopore unit cell to change the magnitude and/or direction a corresponding current.
9. The method as defined in claim 1, further comprising determining waveforms to be applied to nanopore unit cells in the array to achieve net-zero or near-zero total current of the array by a FPGA.
10. The method as defined in claim 1 , wherein the waveform applied to at least one nanopore unit cell is AC.
11. The method as defined in claim 10, wherein the AC waveforms applied to at least two of the nanopore unit cells have different phases.
12. The method as defined in claim 4, wherein a first and second sub-groups are determined, wherein nanopore unit cells included in the first sub-group have forward currents, and wherein nanopore unit cells included in the second sub-group have reverse currents.
13. The method as defined in claim 1, further comprising monitoring the total current of the array of nanopore unit cells.
14. The method as defined in claim 4, further comprising, in response to determining that the total current is not zero or is above a predetermined threshold, re-dividing the array of nanopore unit cells.
15. The method as defined in claim 4, wherein assigning nanopore unit cells to each sub-groups is based at least on a conductivity associated with the individual nanopore unit cells.
16. A nanopore device, comprising: an array of nanopore unit cells, each unit cell having a trans well at the bottom of the unit cell; an application specific integrated circuit (ASIC) layer disposed below the array of nanopore unit cells, wherein the ASIC layer comprises an array of active circuitries; and a processor, the processor configured to: determine a state of a nanopore unit cell of the array; and control the state of the individual nanopore unit cell.
17. The nanopore device as defined in claim 16, further comprising: a cis well and an associated cis electrode on top of the array of nanopore unit cells.
18. The nanopore device as defined in claim 16, wherein an electrolyte solution is filled in the cis well.
19. The nanopore device as defined in claim 16, further comprising: a trans electrode, wherein the trans electrode is disposed in an individual trans well, and wherein the trans electrode is electrically connected with a corresponding active circuitry in the ASIC.
20. The nanopore device as defined in claim 16, wherein the state comprises an open well where no membrane was formed, an intact membrane where no nanopore was formed, a membrane with an open nanopore without an analyte, a membrane with a nanopore in which an analyte is inserted, or a membrane with multiple nanopores.
21. The nanopore device as defined in claim 16, wherein the processor is configured to determine the state of a nanopore unit cell based on the magnitude and/or direction of the current flowing through the cell.
22. The nanopore device as defined in claim 16, wherein the processor is configured to change the states of at least one nanopore unit cell in response to determining that the net current of the array is not zero or is above a predetermined threshold magnitude.
23. The nanopore device as defined in claim 16, wherein the processor is further configured to determine waveforms which can achieve net-zero or near-zero total current in the array of nanopore unit cells.
24. The nanopore device as defined in claim 23, wherein the waveforms applied to at least two of the nanopore unit cells have different phases.
25. The nanopore device as defined in claim 16, wherein the processor is a FPGA.
26. The nanopore device as defined in claim 19, wherein the voltage applied to each individual trans electrode is independently controlled.
PCT/US2025/014933 2024-02-12 2025-02-07 Net-zero current scheme for nanopore system Pending WO2025174659A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463552562P 2024-02-12 2024-02-12
US63/552,562 2024-02-12

Publications (1)

Publication Number Publication Date
WO2025174659A1 true WO2025174659A1 (en) 2025-08-21

Family

ID=94824230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/014933 Pending WO2025174659A1 (en) 2024-02-12 2025-02-07 Net-zero current scheme for nanopore system

Country Status (1)

Country Link
WO (1) WO2025174659A1 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002258A1 (en) 1990-07-27 1992-02-20 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
WO1993010820A1 (en) 1991-11-26 1993-06-10 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
WO1994022892A1 (en) 1993-03-30 1994-10-13 Sterling Winthrop Inc. 7-deazapurine modified oligonucleotides
WO1994024144A2 (en) 1993-04-19 1994-10-27 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
US20090035777A1 (en) 2007-06-19 2009-02-05 Mark Stamatios Kokoris High throughput nucleic acid sequencing by expansion
US20200407786A1 (en) * 2012-11-09 2020-12-31 Roche Sequencing Solutions, Inc. Nucleic acid sequencing using tags
US20210148885A1 (en) * 2019-11-18 2021-05-20 Nooma Bio, Inc. Compact Multipore Array with Embedded Electrodes for Sample Analysis
WO2023049682A1 (en) 2021-09-22 2023-03-30 Illumina, Inc. Sequencing polynucleotides using nanopores
US20230408439A1 (en) * 2022-06-14 2023-12-21 Illumina, Inc. Nanopore sensing systems
WO2024228928A1 (en) 2023-05-03 2024-11-07 Illumina, Inc. Controlled polynucleotide translocation in nanopore sequencing

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002258A1 (en) 1990-07-27 1992-02-20 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO1993010820A1 (en) 1991-11-26 1993-06-10 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
WO1994022892A1 (en) 1993-03-30 1994-10-13 Sterling Winthrop Inc. 7-deazapurine modified oligonucleotides
WO1994024144A2 (en) 1993-04-19 1994-10-27 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
US20090035777A1 (en) 2007-06-19 2009-02-05 Mark Stamatios Kokoris High throughput nucleic acid sequencing by expansion
US20200407786A1 (en) * 2012-11-09 2020-12-31 Roche Sequencing Solutions, Inc. Nucleic acid sequencing using tags
US20210148885A1 (en) * 2019-11-18 2021-05-20 Nooma Bio, Inc. Compact Multipore Array with Embedded Electrodes for Sample Analysis
WO2023049682A1 (en) 2021-09-22 2023-03-30 Illumina, Inc. Sequencing polynucleotides using nanopores
US20230408439A1 (en) * 2022-06-14 2023-12-21 Illumina, Inc. Nanopore sensing systems
WO2024228928A1 (en) 2023-05-03 2024-11-07 Illumina, Inc. Controlled polynucleotide translocation in nanopore sequencing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Practical Handbook of Biochemistry and Molecular Biology", 1989, CRC PRESS, pages: 385 - 394

Similar Documents

Publication Publication Date Title
US11774400B2 (en) Device for sequencing
CN117999360A (en) Nanopore sequencing
AU2018288767B2 (en) Nanopore sequencers
CN111225744B (en) Protein nanopores removal and reinsertion into membranes using osmotic imbalance
US20240319164A1 (en) A circuit design to apply different voltages in a nanopore array
WO2025174659A1 (en) Net-zero current scheme for nanopore system
WO2025174660A1 (en) Recharging for nanopore system
US20240377380A1 (en) Nanopore sensor devices
TW202317993A (en) Isolation of cells in a nanopore sensor array
WO2022211951A1 (en) Nanopore sensor devices
US20230070552A1 (en) Circuit design to apply different voltages in a nanopore array
US20250242348A1 (en) Nanopore sequencing systems
US20250283163A1 (en) A circuit design to measure small current variation in nanopore sequencing
US20240409993A1 (en) Analog circuit to compensate bias offset in amplifier array
US20240319165A1 (en) Nanopore systems and methods of fabrication
US20240110889A1 (en) Fast pulsing for nanopore sensors
TW202303135A (en) Scalable circuit for molecular detection
HK40030450A (en) Nanopore sequencers
HK40030450B (en) Nanopore sequencers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25709001

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载